Vaccines and Global Health: The Week in Review
06 May 2023 :: Issue 702
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at https://centerforvaccineethicsandpolicy.net. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to
David R. Curry, MS
Editor and
Executive Director
Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

Contents [click to move among sections]
:: Coronavirus [COVID-19]
:: Organization Announcements
:: Journal Watch
:: Pre-Print Servers
Milestones, Perspectives

COVID-19

Statement on the fifteenth meeting of the International Health Regulations (2005) Emergency Committee regarding the coronavirus disease (COVID-19) pandemic
5 May 2023 Statement

The WHO Director-General has the pleasure of transmitting the Report of the fifteenth meeting of the International Health Regulations (2005) (IHR) Emergency Committee regarding the coronavirus 2019 disease (COVID-19) pandemic, held on Thursday 4 May 2023, from 12:00 to 17:00 CET.

During the deliberative session, the Committee members highlighted the decreasing trend in COVID-19 deaths, the decline in COVID-19 related hospitalizations and intensive care unit admissions, and the high levels of population immunity to SARS-CoV-2. The Committee’s position has been evolving over the last several months. While acknowledging the remaining uncertainties posted by potential evolution of SARS-CoV-2, they advised that it is time to transition to long-term management of the COVID-19 pandemic.

The WHO Director-General concurs with the advice offered by the Committee regarding the ongoing COVID-19 pandemic. He determines that COVID-19 is now an established and ongoing health issue which no longer constitutes a public health emergency of international concern (PHEIC).

The WHO Director-General considered the advice provided by the Committee regarding the proposed Temporary Recommendations and issued them as per the below statement. The WHO Director-General will convene an IHR Review Committee to advise on Standing Recommendations for the long-term management of the SARS-CoV-2 pandemic, taking into account the 2023-2025 COVID-19 Strategic Preparedness and Response Plan. During this transition, States Parties are advised to continue following the issued Temporary Recommendations. The Director-General expressed his sincere gratitude to the Chair, the Members, and the Advisors of the Committee for their engagement and advice during the last three years...

Temporary Recommendations issued by the WHO Director-General to all States Parties

1. Sustain the national capacity gains and prepare for future events to avoid the occurrence of a cycle of panic and neglect. States Parties should consider how to improve country readiness for future outbreaks. In alignment with WHO guidance, States Parties should update respiratory pathogen pandemic preparedness plans incorporating learnings from national and sub-national After Action Reviews. States Parties should continue to restore health programmes adversely affected by the COVID-19 pandemic.
   - Preparedness and resilience for Emerging Threats;
   - Strengthening pandemic preparedness planning for respiratory pathogens: policy brief;
2. Integrate COVID-19 vaccination into life course vaccination programmes. States Parties should maintain efforts to increase COVID-19 vaccination coverage for all people in the high-priority groups (as defined by the SAGE Roadmap of April 2023) with WHO recommended vaccines and continue to actively address vaccine acceptance and demand issues with communities.

- Global COVID-19 Vaccination Strategy in a Changing World (July 2022 update);
- SAGE Roadmap (Updated March 2023);
- Good practice statement on the use of variant-containing COVID-19 vaccines;
- Continued collaboration with IVAC and others to summarise VE studies, Behavioural and social drivers of vaccination: tools and practical guidance for achieving high uptake.

3. Bring together information from diverse respiratory pathogen surveillance data sources to allow for a comprehensive situational awareness. States Parties should maintain reporting of mortality and morbidity data as well as variant surveillance information to WHO. Surveillance should incorporate information from an appropriate mix of representative sentinel populations, event-based surveillance, human wastewater surveillance, sero-surveillance, and surveillance of selected animal populations known to be at risk of SARS-COV-2. States Parties should leverage the Global Influenza Surveillance and Response System (GISRS) and support the establishment of the WHO Global Coronavirus Laboratory Network (CoViNet).

- Public health surveillance for COVID-19

4. Prepare for medical countermeasures to be authorized within national regulatory frameworks to ensure long-term availability and supply. States Parties should strengthen their regulatory authorities to support long-term authorization and use of vaccines, diagnostics, and therapeutics.

- Therapeutics and COVID-19: living guideline;
- COVID-19 Clinical Care Pathway;
- Emergency Use Listing procedures;
- Prequalification procedures for vaccines;
- Prequalification procedures for in vitro diagnostics

5. Continue to work with communities and their leaders to achieve strong, resilient, and inclusive risk communications and community engagement (RCCE) and infodemic management programmes. State Parties should adapt RCCE and infodemic management strategies and interventions to local contexts.

6. Continue to lift COVID-19 international travel related health measures, based on risk assessments, and to not require any proof of vaccination against COVID-19 as a prerequisite for international travel.

- Interim position paper: considerations regarding proof of COVID-19 vaccination for international travellers;
- Policy considerations for implementing a risk-based approach to international travel in the context of COVID-19

7. Continue to support research to improve vaccines that reduce transmission and have broad applicability; to understand the full spectrum, incidence and impact of post COVID-19 condition and the
evolution of SARS-COV-2 in immunocompromised populations; and to develop relevant integrated care pathways.

Comment on WHO announcement that COVID-19 no longer a Public Health Emergency of International Concern

Statement 5 May 2023 By IFPMA

Commenting on the WHO announcement that COVID-19 is now an established and ongoing health issue which no longer constitutes a public health emergency of international concern (PHEIC), Thomas Cueni, Director General of the International Federation of Pharmaceutical Manufacturers and Association (IFPMA) said:

“The WHO announcement that COVID-19 no longer constitutes a public health emergency of international concern is an important milestone and is a moment to reflect and remember those who lost their lives and those who continue to be impacted by COVID.

“The response to the pandemic was one of incredible resilience, partnership and science. This was underpinned by innovation, voluntary collaborations across the world and decades of research and development – with the biopharmaceutical industry as a key partner to success.

“It is critical that we carefully reflect on what worked well and what did not, taking the lessons from this extraordinary, collective effort so that the world is better prepared against future pandemics.

“We need to preserve the strength of the innovation ecosystem, which fostered the development and scaling up of vaccines, treatments, and diagnostics at record speed and record scale. In particular, we must not undermine what worked well against COVID-19 – the innovation ecosystem and the unhindered access to pathogens – and we must work together to tackle the shortcomings we encountered. This includes inequitable rollout of vaccines, tests, and treatments as well as strengthening health system capacity to respond to any future pandemic and to address the problems of non-communicable diseases and lack of Universal Health Coverage (UHC).”

CDC

Walensky Announces Departure from CDC

May 5, 2023

CDC Director Dr. Rochelle Walensky announced today her intent to depart the agency at the end of June. Walensky has led CDC through a transition to greater normalcy across the country, after two years of COVID-19 related closures and waves of dangerous, new virus variants. She also launched Moving Forward – a wide-ranging set of reforms designed to strengthen CDC communications and response operations. Walensky described this moment for the agency and the country in a letter to President Joe Biden.

“The end of the COVID-19 public health emergency marks a tremendous transition for our country, for public health, and in my tenure as CDC Director,” Walensky wrote. “I took on this role, at your request,
with the goal of leaving behind the dark days of the pandemic and moving CDC – and public health – forward into a much better and more trusted place. In the process, we saved and improved lives and protected the country and the world from the greatest infectious disease threat we have seen in over 100 years.”

Importantly, Walensky helped restore morale and a sense of normalcy to an agency that had been enduring significant public adversity related to the COVID-19 pandemic.

“Dr. Walensky has saved lives with her steadfast and unwavering focus on the health of every American,” President Joe Biden said. “As Director of the CDC, she led a complex organization on the front lines of a once-in-a-generation pandemic with honesty and integrity. Dr. Walensky leaves CDC a stronger institution, better positioned to confront health threats and protect Americans. We have all benefited from her service and dedication to public health, and I wish her the best in the next chapter.”...

While at CDC, I had the true gift of meeting, working with, and giving voice to thousands of people at the agency who work 24/7 to worry about health and public health so that the rest of the nation does not have to,” Walensky said. “I have never been prouder of anything I have done in my professional career.”...

::::::
::::::

“Zoonotic Spillover”

Quadripartite welcomes OHHLEP’s new white paper on zoonotic spillover prevention

Joint Statement
Published on 3 May 2023
Rome/Paris/Geneva/Nairobi –
At the request of the Quadripartite organizations, the One Health High-Level Expert Panel (OHHLEP) recently published a white paper calling for enhanced prevention of zoonotic spillover within the triad of Pandemic Prevention, Preparedness, and Response. The paper advocates for the need to reduce the risk of zoonotic disease spillover at source through improved prevention measures, an approach that is more efficient than relying on disease detection and response.

In view of current opportunities – including the negotiations for a new pandemic instrument and the Pandemic Fund for prevention, preparedness and response – the Quadripartite welcomes OHHLEP’s call to promote prevention, align strategies, fill gaps, and sustain risk reduction.

The paper states “(It’s) clear that pandemic prevention at the source cannot continue as an afterthought – a much larger commitment is overdue and sorely needed to prevent future pandemics”. It highlights that efforts to prevent epidemics usually only begin after a microorganism (pathogen) has already made the leap from animals to humans (described as a spillover event), allowing a given disease to re-emerge or new ones to emerge. It recommends distinguishing containment of outbreak activities from those targeting the prevention of spillover. This intends to draw attention to the lack of emphasis and resources currently devoted to prevention and the reduction of risks at source.
The OHHLEP proposes the following definition: “Prevention of pathogen spillover from animals to humans means shifting the infectious disease control paradigm from reactive to proactive (primary prevention). Prevention includes addressing the drivers of disease emergence, namely ecological, meteorological and anthropogenic factors and activities that increase spillover risk, in order to reduce the risk of human infection. It is informed by, amongst other actions, biosurveillance in natural hosts, people and the environment, understanding pathogen infection dynamics and implementing intervention activities.”

The OHHLEP is a key advisory group to the Quadripartite, comprising the Food and Agriculture Organization of the United Nations (FAO), the United Nations Environment Programme (UNEP), the World Health Organization (WHO) and the World Organisation for Animal Health (WOAH).
'Lessons from the Covid War': The report from the Covid Crisis Group
Book  Hachette, 2022
A joint effort from: Danielle Allen, John M. Barry, John Bridgeland, Michael Callahan, Nicholas A. Christaki, Doug Criscitello, Charity Dean, Victor Dzau, Gary Edson, Ezekiel Emanuel, Ruth Faden, Baruch Fischhoff, Margaret "Peggy" Hamburg, Melissa Harvey, Richard Hatchett, David Heymann, Kendall Hoyt, Andrew Kilianski, James Lawler, Alexander J. Lazar, James Le Duc, Marc Lipsitch, Anup Malani, Monique K. Mansoura, Mark McClellan, Carter Mecher, Michael Osterholm, David A. Relman, Robert Rodriguez, Carl Schramm, Emily Silverman, Kristin Urquiza, Rajeev Venkayya, Philip Zelikow

Description
This powerful report on what went wrong—and right—with America’s Covid response, from a team of 34 experts, shows how Americans faced the worst peacetime catastrophe of modern times.

Our national leaders have drifted into treating the pandemic as though it were an unavoidable natural catastrophe, repeating a depressing cycle of panic followed by neglect. So a remarkable group of practitioners and scholars from many backgrounds came together determined to discover and learn lessons from this latest world war.

*Lessons from the Covid War* is plain-spoken and clear sighted. It cuts through the enormous jumble of information to make some sense of it all and answer: What just happened to us, and why? And crucially, how, next time, could we do better? Because there will be a next time.

The Covid war showed Americans that their wondrous scientific knowledge had run far ahead of their organized ability to apply it in practice. Improvising to fight this war, many Americans displayed ingenuity and dedication. But they struggled with systems that made success difficult and failure easy.

This book shows how Americans can come together, learn hard truths, build on what worked, and prepare for global emergencies to come.

::::::::::

**PHEIC**

*Coronavirus [COVID-19]*

*Public Health Emergency of International Concern (PHEIC)*


**Weekly Epidemiological and Operational updates**

*Last update: 29 March 2023*

**Confirmed cases**: 765 222 932

**Confirmed deaths**: 6 921 614

**Vaccine doses administered**: 13 346 989 954

**Weekly epidemiological update on COVID-19 - 4 May 2023**

*Overview*

Globally, nearly 2.8 million new cases and over 17 000 deaths were reported in the last 28 days (3 to 30 April 2023), a decrease of 17% and 30%, respectively, compared to the previous 28 days (6 March to 2 April 2023). The picture is mixed at the regional level, with increases in reported cases and deaths...
seen in the South-East Asia, Eastern Mediterranean, and Western Pacific regions, and decreases in other regions. As of 30 April 2023, over 765 million confirmed cases and over 6.9 million deaths have been reported globally.

Figure 1. COVID-19 cases reported by WHO Region, and global deaths by 28-day intervals, as of 30 April 2023**

Global Dashboard on COVID-19 Vaccine Equity
The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

Dashboard on Vaccine Equity [accessed 06 May 2023]: https://data.undp.org/vaccine-equity/
See also visualization on Vaccine Access and Vaccine Affordability

Last Update: Apr 26, 2023

Duke – Launch and Scale Speedometer
The Race for Global COVID-19 Vaccine Equity
See our COVID Vaccine Purchases research
Overview of donations by top 10 donating countries

Our World in Data

**Coronavirus (COVID-19) Vaccinations**  [Accessed 06 May 2023]

:: 70% of the world population has received at least one dose of a COVID-19 vaccine.
:: 13.38 billion doses have been administered globally, and 174,628 are now administered each day.
:: 29.8% of people in low-income countries have received at least one dose.

**U.S.: COVID-19/Vaccines – Announcements/Regulatory Actions/Deployment**
HHS

HHS Secretary Xavier Becerra Statement on CDC Director

May 5, 2023   News Release

Today, U.S. Department of Health and Human Services (HHS) Secretary Xavier Becerra released the following statement on Centers for Disease Control and Prevention (CDC) Director Dr. Rochelle Walensky’s announcement that she plans to depart the public health agency at the end of June:

“Dr. Walensky helped lead an unprecedented whole-of-government response during a historic pandemic.

“We are living our lives again and the American people are safer now because Dr. Walensky led the CDC with real facts and science. She did not yield to the pressures of expediency or politics. And she always put people first.

“Under her direction, we began the critically important work of modernizing our public health infrastructure and she leaves the CDC better positioned to respond to public health threats. Working alongside Dr. Walensky as a partner and friend has been an immense honor. I thank her for her leadership and look forward to witnessing her future successes.”

FDA

Press Announcements

May 3, 2023 - FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine

Today, the U.S. Food and Drug Administration approved Arexvy, the first respiratory syncytial virus (RSV) vaccine approved for use in the United States. Arexvy is approved for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older.

“Older adults, in particular those with underlying health conditions, such as heart or lung disease or weakened immune systems, are at high risk for severe disease caused by RSV,” said Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research. “Today’s approval of the first RSV vaccine is an important public health achievement to prevent a disease which can be life-threatening and reflects the FDA’s continued commitment to facilitating the development of safe and effective vaccines for use in the United States.”

FDA VRBPAC

Advisory Committee Calendar

Vaccines and Related Biological Products Advisory Committee May 18, 2023 Meeting Announcement - 05/18/2023

On May 18, 2023, the committee will meet in open session to discuss and make recommendations on the safety and effectiveness of ABRYSVO (Respiratory Syncytial Virus Vaccine), manufactured by Pfizer Inc., with a requested indication, in Biologics License Application (BLA) 125768 (STN 125768/0), for the prevention of lower respiratory tract disease and severe lower respiratory tract disease caused by RSV in infants from birth through 6 months of age by active immunization of pregnant individuals.

Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

European Medicines Agency [EMA]

News & Press Releases
News: Review of transparency rules for the EU Clinical Trials Information System (CTIS) (new)
Last updated: 03/05/2023

European Centre for Disease Prevention and Control
https://www.ecdc.europa.eu/en
News/Updates/Reports [Selected]
News
Weekly COVID-19 country overview
Epidemiological update - 5 May 2023

Joint ECDC-WHO/Europe mpox (monkeypox) surveillance bulletin
Epidemiological update - 4 May 2023

Africa: COVID-19 – Announcements/Regulatory Actions/Deployment
https://africacdc.org/covid-19-vaccination/

Africa CDC COVID-19 Vaccine Dashboard
Safeguarding Africa's Health

Vaccine Administration based on Eligible Population (Click to View Entire Population)

1126.7M Vaccine Doses Received
95.8% % Doses Utilized

1079.5M Vaccine Doses Administered
51.6% % Coverage (Fully Vaccinated)

(Last Update - May 1, 2023)

China: COVID-19/Vaccines – Announcements/Regulatory Actions/Deployment

National Medical Products Administration – PRC [to 06 May 2023]
http://english.nmpa.gov.cn/
News
COVID global emergency over but risks remain, says China health official
SHENZHEN, China, May 6 (Reuters) - While the World Health Organization (WHO) has declared an end to the global emergency status for COVID-19, the virus remains harmful and China will continue to monitor it while increasing vaccinations among high-risk groups, a top Chinese health official said...

The ending of the alert status does not mean COVID will disappear, but its impact can now be effectively controlled, Liang Wannian, head of China's COVID response expert panel under the National Health Commission, said in an interview with state media CCTV published on Saturday.

China will continue to monitor mutations of the virus, strengthen vaccinations among high risk and key groups, and look to improve COVID treatment capabilities, Liang said...

::::::

Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Russia: Sputnik V – "the first registered COVID-19 vaccine"
https://sputnikvaccine.com/newsroom/pressreleases/
Press Releases
No new digest content identified. Last press release issued 31.08.2022.

::::::

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Government of India – Press Information Bureau
Latest Press Releases
No new digest content identified.

Indian Council for Medical Research (ICMR)
https://www.icmr.gov.in/media.html
Press Releases
No new digest content identified.

Ministry of Health and Family Welfare
https://www.mohfw.gov.in/
PHEIC
Mpox
Public Health Emergency of International Concern (PHEIC)
https://www.who.int/emergencies/situations/monkeypox-oubreak-2022

Last Update:
Multi-country outbreak of mpox, External situation report#21 - 27 April 2023

PHEIC
Polio
Polio this week as of 03 May 2023 - GPEI
Headlines [Selected]
- A key priority in 2023 is to end both wild- and variant polio transmission around the world by focusing on the most consequential geographies where children are at the highest risk of encountering and spreading the virus, and which collectively accounted for 90% of all new polio cases worldwide in 2022. Northern Nigeria is one of these seven subnational areas that now hold the key to a polio-free world. Read more...

Summary of new polioviruses this week:
- Côte d’Ivoire: one cVDPV2 case
- Madagascar: eight cVDPV1 positive environmental samples

UN OCHA – Current Emergencies
Current Corporate Emergencies
Afghanistan
Editor’s Note:
We observe that OCHA has removed Afghanistan from its listing of "Current Emergencies." We did not identify any explanation for its removal.

Northern Ethiopia
No new digest content identified.

Somalia
No new digest content identified.

Türkiye/Syria Earthquakes
No new digest content identified.

Ukraine
WHO & Regional Offices [to 06 May 2023]

https://www.who.int/news
Selected News/Announcements/Statements
5 May 2023  Statement
Statement on the fifteenth meeting of the International Health Regulations (2005) Emergency Committee regarding the coronavirus disease (COVID-19) pandemic

3 May 2023  Joint News Release
Quadripartite welcomes OHHLEP’s new white paper on zoonotic spillover prevention

3 May 2023  News release
Collaborating locally is key for progress globally towards health-related SDGs

2 May 2023  News release
New survey results show health systems starting to recover from pandemic

1 May 2023  Departmental news
WHO Convenes Workshop on Achieving Quality and Sustainable Local Vaccine Production in Africa to Improve Access

1 May 2023  Departmental news
Public consultation of experts to join the Guideline Development Group (GDG) for Defeating Meningitis by 2030 Roadmap: Meningitis diagnosis, treatment and care guidelines

1 May 2023  Departmental news
WHO Director-General and Civil Society Task Force on TB release joint statement on key priorities in the lead up to 2nd UN High-Level Meeting on TB

WHO Regional Offices

WHO African Region
:: Empowering communities to fight cholera misinformation in Malawi  04 May 2023
:: Sierra Leone launches review to reinforce health emergency readiness, response  03 May 2023

WHO Region of the Americas PAHO
:: 4 May 2023  A new organizational structure to strengthen PAHO’s technical cooperation
Washington, DC, May 4, 2023 – Under the leadership of the new Director, Jarbas Barbosa, and in keeping with the Pan American Health Organization's commitment and vision to address the new and
emerging priorities in health, a decision was made to adjust the organizational structure of the Pan American Sanitary Bureau (PASB). The new organizational...

:: 4 May 2023  **With rising cases, experts discuss Chikungunya spread in the Americas**
Washington D.C. 4 May 2023 (PAHO) – As cases of chikungunya in the region of the Americas reach over 210,000 in the first months of 2023, experts reviewed in a webinar this week methods to control the disease vector, factors that facilitate its spread and support to countries to tackle a growing number of cases. Chikungunya is a disease...

:: 4 May 2023  **At OAS, PAHO Director presents update on health progress in the Americas**
Washington D.C. 4 May 2023 (PAHO) – Yesterday, the 2022 report of the Director of the Pan American Health Organization (PAHO) was presented by Dr. Jarbas Barbosa during a session of the Permanent Council of the Organization of American States (OAS) in Washington D.C. During his presentation, the PAHO Director updated OAS ambassadors and staff on...

:: 4 May 2023  **PAHO and Grindr join efforts to provide key information on mpox to LGBTQI+ communities in the Americas**
Washington D.C 4 May 2023 (PAHO) – The Pan American Health Organization (PAHO) announced a groundbreaking initiative with Grindr LLC (Grindr) through its social networking app, to ensure key information on monkeypox (mpox) reaches lesbian, gay, bisexual, transgender, queer or questioning, intersex and more (LGBTQI+) communities in the Region of...

:: 2 May 2023  **PAHO and AIDS Healthcare Foundation to collaborate on elimination of HIV/AIDS, tuberculosis, and other infectious diseases in Latin America and the Caribbean**
Washington, DC, May 2, 2023 (PAHO) - The Pan American Health Organization (PAHO) and the AIDS Healthcare Foundation (AHF) have agreed to work together to contribute to efforts to eliminate HIV/AIDS, tuberculosis (TB), viral hepatitis, mpox and other sexually transmitted infections such as syphilis in Latin America and the Caribbean. The framework...

**WHO South-East Asia Region** SEARO
:: 5 May 2023  Statement
**World Hand Hygiene Day: Accelerate action together**

**WHO European Region** EURO
:: 3 May 2023  News release
**Countries hosting Ukrainian refugees reaffirm their commitment to meeting their health needs**
:: 1 May 2023  News release
**Focusing on the state of health in Ukraine with an eye to the future**

**WHO Western Pacific Region**
No new digest content identified.

::::

**Disease Outbreak News (DONs)**
Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.
Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

**5 May 2023 | Acute hepatitis E – South Sudan**
4 May 2023 | Measles - Ethiopia

1 May 2023 | Lassa fever - Nigeria

::: New WHO Publications:::

https://www.who.int/publications/i

Selected
5 May 2023

**WHO research for hand hygiene in health care 2023–2030: summary**

5 May 2023

**Twentieth meeting of the United Nations Inter-Agency Task Force on the Prevention and Control of Non-communicable...**

5 May 2023

**Data management competency framework**

*Overview*

The effective use of data in the management and delivery of public health services has long been understood as critical. The Data Management Competency Framework was developed to be a practical tool providing both a structure and methodology to enable the health workforce, including both decision-makers and implementors, to identify capacity gaps and define the competencies required for the whole data life cycle at all levels of health organizations. It includes 4 areas which are further subdivided into seventeen domains, each with a set of knowledge and skills across 4 proficiency levels. The framework can empower Member States to drive strategic, integrated, and sustainable health workforce capacity building.

4 May 2023

**Assessment tool on infection prevention and control minimum requirements for primary health care facilities**

4 May 2023

**A framework for the quantification and economic valuation of health outcomes originating from health and non-health climate change mitigation and adaptation action**

*Overview*

This report presents a framework to link science, policy and practice for a comprehensive assessment of climate mitigation and adaptation investments and their impact on human health. The framework proposes to use weather and climate data to forecast health impacts over time, as well as biophysical and economic models to quantify the outcomes of investments in climate change adaptation and mitigation for relevant sectoral indicators and health co-benefits. It provides guidance on the economic valuation of health co-benefits of climate action, for inclusion in sector-specific cost–benefit analysis (CBA), including the spatial allocation of such costs and benefits.

The framework developed and presented in this study is comprehensive, and provides various entry points for different audiences, including decision-makers in the public and private sectors, researchers and scientists, working in the health sector as well as in other thematic areas and related sectors affected by climate action.
3 May 2023
**How school systems can improve health and well-being: topic brief: mental health**

3 May 2023
**How school systems can improve health and well-being: topic brief: water, sanitation and hygiene (WASH)**

3 May 2023
**How school systems can improve health and well-being: topic briefs: nutrition**

3 May 2023
**How school systems can improve health and well-being: topic brief: substance use**

3 May 2023
**From emergency response to long-term COVID-19 disease management: sustaining gains made during the COVID-19...**

3 May 2023
**2023 progress report on the Global Action Plan for Healthy Lives and Well-being for All**

2 May 2023
**Guidance on operational microplanning for COVID-19 vaccination, revised 2 May 2023**

*Overview*

This document outlines the eight step process for COVID-19 vaccination microplanning supporting planners and immunization programme managers at the national and sub-national levels for implementation. This supersedes the previous version (published in 16 Nov 2021) and the revisions emphasizes the benefits of integrating COVID-19 vaccination with routine immunization and primary health care services. It includes new information on WHO’s global COVID-19 vaccination strategy and related monitoring metrics, WHO SAGE roadmap on optimal use of uses of COVID-19 vaccines in the context of omicron and substantial population immunity, good practice statement on the use of variant-containing COVID-19 vaccines, geo-enabled microplanning and more.

2 May 2023
**Report of the second meeting of the Technical Advisory Group on NCD-related Research and Innovation**

1 May 2023
**Fourth round of the global pulse survey on continuity of essential health services during the COVID-19...**

1 May 2023
Walensky Announces Departure from CDC
May 5, 2023
CDC Director Dr. Rochelle Walensky announced today her intent to depart the agency at the end of June. Walensky has led CDC through a transition to greater normalcy across the country, after two years of COVID-19 related closures and...

ACIP Meetings
Next ACIP Meeting: June 21-22

MMWR Weekly
May 5, 2023 / No.18
COVID-19 Mortality Update — United States, 2022

Coronavirus Disease 2019 (COVID-19)- CDC
Announcements/reports/data summaries [Selected]
5/5/23
EARLY RELEASE: COVID-19 Surveillance After Expiration of the Public Health Emergency Declaration — United States, May 11, 2023
Summary
What is already known about this topic?
Authorizations to collect certain public health data expire at the end of the U.S. public health emergency declaration on May 11, 2023.
What is added by this report?
Changes to the national COVID-19 monitoring strategy and COVID Data Tracker capitalize on marked improvements in multiple surveillance systems. Weekly COVID-19 hospital admission levels and the percentage of all COVID-19–associated deaths will be primary surveillance indicators. Emergency department visits and percentage of positive SARS-CoV-2 laboratory test results will help detect early changes in trends. Genomic surveillance will continue to help identify and monitor SARS-CoV-2 variants.
Clean Hands, Healthy Lives: Increasing Investments in Hand Hygiene in Africa
5 May 2023
A Call to Action By Dr. Jean Kaseya, Director General, Africa CDC

::::::
::::::

China CDC
http://www.chinacdc.cn/en/

National Health Commission of the People's Republic of China [to 06 May 2023]
http://en.nhc.gov.cn/
News
No new digest content identified.

National Medical Products Administration — PRC [to 06 May 2023]
http://english.nmpa.gov.cn/
News
No new digest content identified.

China CDC Weekly Reports: Current Volume (5)
2023-05-05 / No. 18 COVID-19 ISSUE (38)
View PDF of this issue
- Preplanned Studies: The Associated Factors of SARS-CoV-2 Reinfection by Omicron Variant — Guangdong Province, China, December 2022 to January 2023
- Preplanned Studies: Timing and Magnitude of the Second Wave of the COVID-19 Omicron Variant — 189 Countries and Territories, November 2021 to February 2023
- Preplanned Studies: The Infection of Healthcare Workers and the Reinfection of Patients by Omicron Variant — Jiangsu Province, China, December 2022 to January 2023

::::::
::::::

Organization Announcements

Paul G. Allen Frontiers Group [to 06 May 2023]
https://alleninstitute.org/news-press/
News
Hongkui Zeng elected to the National Academy of Sciences
05.02.2023
Zeng was chosen for her contributions to understanding the cells and connections of the brain.

BMGF - Gates Foundation [to 06 May 2023]
https://www.gatesfoundation.org/ideas/media-center
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people.

News: Articles and Publications
No new digest content identified.

CARB-X [to 06 May 2023]
https://carb-x.org/
News
No new digest content identified.

Center for Vaccine Ethics and Policy – GE2P2 Global Foundation [to 06 May 2023]
https://centerforvaccineethicsandpolicy.net/
News/Analysis/Publications-Digests/Statements
:: Vaccines and Global Health: The Week in Review - 22 April 2023
:: Informed Consent: A Monthly Review – April 2023
:: Genomic Medicine – Governance, Ethics, Policy, Practice: A Monthly Digest – April 2023
:: Public Consultations Watch :: Global Calls for Input/Public Comment/RFIs - 03 May 2023 – Issue 03

CEPI – Coalition for Epidemic Preparedness Innovations [to 06 May 2023]
http://cepi.net/
Latest News
No new digest content identified.

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 06 May 2023]
https://cioms.ch/
News; Publications; Events
CIOMS Cumulative Glossary, with a focus on Pharmacovigilance (Version 2.1)
The CIOMS Cumulative Glossary is an organized collection of the terms and definitions included in published CIOMS Working Group reports, with a focus on pharmacovigilance. It includes links to the reports and, where applicable, provides references to the sources from which the definitions were adopted or modified. Version 2.1 covers the terms included in thirteen different CIOMS reports published between 1992 and 2022. It does not cover CIOMS reports on the subjects of ethics, clinical pharma...
Year of publication: 2023  Number of pages: 144  SKU: 7912
Gender considerations in health research
The meeting report is now available from the CIOMS / GENDRO joint meeting held on 2 February 2023.

CIOMS Glossary of ICH terms and definitions: Version 3 now available
Version 3 of the CIOMS Glossary of ICH terms and definitions is now freely available here. It can also be accessed from the ICH webpage here.

DARPA – Defense Advanced Research Projects Agency [U.S.] [to 06 May 2023]
https://www.darpa.mil/news
News
No new digest content identified.

Duke Global Health Innovation Center [to 06 May 2023]
https://dukeghic.org/
Our Blog
No new digest content identified.

EDCTP [to 06 May 2023]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
News
No new digest content identified.

Emory Vaccine Center [to 06 May 2023]
http://www.vaccines.emory.edu/
Vaccine Center News
No new digest content identified.

European Vaccine Initiative [to 06 May 2023]
http://www.euvaccine.eu/
Latest News, Events
No new digest content identified.

Evidence Aid [to 06 May 2023]
Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.
http://www.evidenceaid.org/
Resources [Selected]
No new digest content identified.

**Fondation Merieux** [to 06 May 2023]
http://www.fondation-merieux.org/
News, Events
No new digest content identified.

**Gavi** [to 06 May 2023]
https://www.gavi.org/
News Releases
No new digest content identified.

**GHIT Fund** [to 06 May 2023]
https://www.ghitfund.org/newsroom/press
Press Releases
March 30, 2023
A Total of Approximately 400 Million Yen Investment in Eisai, Ehime University, DNDi and Others for New Drug and Vaccine Development for Neglected Tropical Diseases
The Global Health Innovative Technology (GHIT) Fund announced today an investment totaling approximately 400 million yen (US$2.9 million) for the research and development of new drugs against mycetoma and onchocerciasis, which are Neglected Tropical Diseases (NTDs), as well as a vaccine against malaria.

**Global Fund** [to 06 May 2023]
News & Stories
No new digest content identified.

**Global Research Collaboration for Infectious Disease Preparedness [GloPID-R]** [to 06 May 2023]
https://www.globid-r.org/news/
News
Launch of a new tool for funders: Living Roadmap will support stronger coordination of clinical trial responses to epidemics and pandemics
May 4, 2023
The *GloPID-R Funders Living Roadmap for Clinical Trial Coordination* is now publicly available on the GloPID-R website. Setting out clear goals, principles and recommendations, it represents a valuable tool for funders and other stakeholders. This Living Roadmap will contribute to improving global capacity to deliver coordinated, effective and equitable clinical trials in response to epidemics and pandemics.

**Hilleman Laboratories** [to 06 May 2023]
Geneva (ICRC) – An estimated 100,000 people fleeing increased violence in Sudan are already seeking safety in neighboring countries including the Central African Republic, South Sudan, Egypt, Ethiopia and Chad.

04-05-2023 | News release

Health Care in Danger Strategy: Assessment Report
    This evaluation, completed in August 2022, assessed the ICRC's Health Care in Danger Strategy.
02-05-2023 | Report

Call for briefing papers | Data Protection and Cybersecurity in Humanitarian Action
    It is for this reason that we are launching a call for briefing papers for the 2024 Symposium on Cybersecurity and Data Protection in Humanitarian Action in Luxembourg, which is tentatively scheduled for 23-25 January 2024. Topics #1 Expanding on the f
02-05-2023 | Article

Published on 3 May 2023
Long COVID: The Persistence of SARS-CoV-2 in the Mucous Membranes May Be A Factor

International Coalition of Medicines Regulatory Authorities [ICMRA]
Selected Statements, Press Releases, Research
No new digest content identified.

IFFIm
http://www.iffim.org/
Press Releases/Announcements
No new digest content identified.

IFRC [to 06 May 2023]
Press Releases [Selected]
Press release 04/05/2023
IFRC increases support in Sudan to assist people in at-risk locations and on the move

Press release 31/03/2023
Vanuatu: One month on since double cyclones, rising cases of Leptospirosis a concern

Institut Pasteur [to 06 May 2023]
Press Documents
No new digest content identified.

ISC / International Science Council [to 06 May 2023]
https://council.science/current/
ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils. 
Press releases
ISC Statement on Nicaragua
The ISC expresses its concern regarding repression of scientific freedoms in Nicaragua.
Paris, France 5 May 2023
The International Science Council (ISC) expresses its deep concern regarding government repression of scientific freedoms in Nicaragua and warns against the detrimental impact the resulting loss of knowledge and expertise will have for the peaceful and sustainable development of the country.
The ISC is committed to upholding the principle of freedom and responsibility in science, which lays out freedoms that are fundamental to scientific advancement and to human and environmental wellbeing. In Nicaragua, these scientific freedoms have been severely compromised by ongoing and escalating government interference in institutional autonomy and suppression of the country’s scientific and research communities....
International Union of Immunological Societies (IUIS)
https://iuis.org/
News/Events [Selected]
No new digest content identified.

IVAC  [to 06 May 2023]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
Updates; Events
No new digest content identified.

IVI  [to 06 May 2023]
http://www.ivi.int/
IVI News & Announcements
IVI receives grand prize for running exemplary IACUC to ensure protection of laboratory animals

Call for Applications: 2023 Introductory Course for Standard Practice (GxP) organized by the Global Training Hub for Biomanufacturing (GTH-B)

Johns Hopkins Center for Health Security  [to 06 May 2023]
https://www.centerforhealthsecurity.org/news/center-news/
Center News  [Selected]
News [Selected]
Center for Health Security submits RFI with recommendations to reform and strengthen the Centers for Disease Control and Prevention (CDC)
May 1, 2023 – The Johns Hopkins Center for Health Security recently provided feedback and suggestions in response to a Request for Information (RFI) from Representative Mariannette Miller-Meeks on how the US Congress can strengthen and reform the Centers for Disease Control and Prevention (CDC). The Center for Health Security believes that an adequately funded, appropriately authorized, and nimble CDC with a target mission is crucial to ensuring the public’s health and maintaining community resilience. The Center's recommendations draw heavily from our "Building the CDC the Country Needs" report, written under the auspices of The Center for Strategic and International Studies (CSIS) Commission Working Group on the CDC, co-authored by the Director of our Center, and supported by 38 signatories, including experts on the CDC’s state and local partners, pandemic preparedness, and policymaking...

MSF/ Médecins Sans Frontières  [to 06 May 2023]
http://www.msf.org/
Latest [Selected Announcements]
Burkina Faso
Severe humanitarian crisis persists for people living under blockade in Djibo
Sudan

Severe medical needs persist amidst conflict in Sudan

Voices from the Field 4 May 2023

National Academy of Medicine - USA [to 06 May 2023]
https://nam.edu/programs/
News [Selected]
No new digest content identified.

National Academy of Sciences - USA [to 06 May 2023]
https://www.nationalacademies.org/newsroom?
News
News Release | May 4, 2023
WASHINGTON — Nonhuman primate research supported by the National Institutes of Health is critical to the nation’s ability to respond adequately to public health emergencies and carry out high-impact biomedical research — but gaps in the systems that support research using these animal models are undermining the U.S. biomedical research enterprise and national health emergency readiness, says a new National Academies of Sciences, Engineering, and Medicine report.

Registration Now Open -- May 24-26 Nobel Prize Summit on Misinformation and Trust in Science
March 19, 2023
Registration is now open for the Nobel Prize Summit ‘Truth Trust and Hope’ a global conversation on how to stop misinformation from eroding public trust in science. Hosted by NAS and the Nobel Foundation the summit takes place May 24-26 in Washington D.C. and virtually.

National Vaccine Program Office - U.S. HHS [to 06 May 2023]
https://www.hhs.gov/vaccines/about/index.html
Upcoming Meetings/Latest Updates
National Vaccine Advisory Committee (NVAC)
June 15-16, 2023 NVAC Meeting

NIH [to 06 May 2023]
http://www.nih.gov/
News Releases
NIH study identifies features of Long COVID neurological symptoms
Findings offer insight into biological mechanisms, pointing to possible treatments.
Friday, May 5, 2023
PATH  [to 06 May 2023]
https://www.path.org/media-center/
Press Releases

Tarryn Haslam to join PATH as new Director of Malaria and Neglected Tropical Diseases program
PATH is pleased to announce that Tarryn Haslam will join our organization and serve as Director of the Malaria and Neglected Tropical Diseases (MNTD) program, effective May 16.

PATH CEO announces senior leadership appointments
May 4, 2023 by PATH
PATH is pleased to announce the promotion of two PATH veterans to leadership positions in its global organization. These leaders bring nearly three decades of PATH experience to their new appointments, in addition to expertise within the global health sector and beyond. The new appointments are as follows:

Chief of External Affairs - Heather Ignatius
To oversee communications and marketing, advocacy and public policy, and philanthropic development for PATH, Heather Ignatius has been promoted to Chief of External Affairs to lead the External Affairs Division.
Heather has been a part of the PATH team for more than 10 years and has been a driving force in our advocacy and policy efforts, leading a global team advancing national and global policy change across a diverse array of public health issues...

Global Head of Center for Vaccine Innovation and Access - Jessica Millman
PATH is pleased to announce that Jessica Millman is our new Global Head of the Center for Vaccine Innovation and Access (CVIA,). In this role, Jessica will lead a global team and a complex portfolio spanning 18 disease areas and several dozen projects. Jessica has been leading CVIA in an interim capacity since October 2022, managing our work to develop and deliver lifesaving vaccines to communities around the world...

Rockefeller Foundation  [to 06 May 2023]
https://www.rockefellerfoundation.org/
Selected Reports/Press Releases
No new digest content identified.

Sabin Vaccine Institute  [to 06 May 2023]
https://www.sabin.org/press/
Latest News & Press Releases
No new digest content identified.

UNAIDS  [to 06 May 2023]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
5 May 2023
Moldova expands harm reduction services to all prisons
4 May 2023
Leave no one behind and that includes people who use drugs

1 May 2023

**African ministers of finance join forces to highlight the importance of financial sustainability in the response to HIV**

**UNICEF** [to 06 May 2023]
https://www.unicef.org/media/press-releases

*Latest press releases, news notes and statements*

**Statement** 04 May 2023

**Statement by UNICEF Executive Director Catherine Russell on the escalating humanitarian crisis in Sudan**

NEW YORK/NAIROBI, 4 May 2023 – "The situation in Sudan is teetering toward catastrophe, and children are increasingly caught in the crossfire. While we are unable to confirm estimates due to the intensity of the violence, UNICEF has received reports that 190 children have been killed and another 1,700 injured in Sudan since conflict erupted almost...

**Remarks** 03 May 2023

**UNICEF Executive Director Catherine Russell's remarks at the 2023 Global Report on Food Crises launch event**

"Excellencies, colleagues ... it is good to be with you today for this critically important discussion. UNICEF looks forward to expanding our work with the Global Network against Food Crises, especially given the disproportionate impact food and nutrition insecurity have on children and women. "The findings presented in this year’s Global Report...

**Press release** 03 May 2023

**Global Report on Food Crises: Number of people facing acute food insecurity rose to 258 million in 58 countries in 2022**

Rome/Brussels/New York/Washington, D.C. - The number of people experiencing acute food insecurity and requiring urgent food, nutrition and livelihood assistance increased for the fourth consecutive year in 2022, with over a quarter of a billion facing acute hunger and people in seven countries on the brink of starvation, according to the latest...

**Unitaid** [to 06 May 2023]
https://unitaid.org/

**Featured News**

*No new digest content identified.*

**Vaccine Equity Cooperative [nee Initiative]** [to 06 May 2023]
Eight new Discovery Research Platforms will break down barriers in research

From cells to societies, Wellcome is directing £73mn to boost transformative research environments which empower researchers to overcome specific barriers to progress in their fields.

Wistar Scientists Discover Innate Tumor Suppression Mechanism

Findings could benefit African Americans who possess a specific genetic variant of p53
Press Releases
No new digest content identified.

World Organisation for Animal Health (OIE)  [to 06 May 2023]
https://www.oie.int/en/
Press Releases, Statements
Joint Statement
Quadripartite welcomes OHHLEP’s new white paper on zoonotic spillover prevention
Published on 3 May 2023

ARM [Alliance for Regenerative Medicine]  [to 06 May 2023]
Selected Press Releases
No new digest content identified.

BIO  [to 06 May 2023]
Press Releases
No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network  [to 06 May 2023]
http://www.dcvmn.org/
News; Upcoming events
No new digest content identified.

ICBA – International Council of Biotechnology Associations  [to 06 May 2023]
https://internationalbiotech.org/news/
News
No new digest content identified.

IFPMA  [to 06 May 2023]
https://ifpma.org/
Selected Press Releases, Statements, Publications
Statement  5 May 2023
Comment on WHO announcement that COVID-19 no longer a Public Health Emergency of International Concern
By IFPMA

International Alliance of Patients’ Organizations – IAPO  [to 06 May 2023]
https://www.iapo.org.uk/news/topic/6
Save the date: 10th Global Patients Congress
We are delighted to announce that IAPO's 10th Global Patients Congress (GPC 2023) - "Innovative patient partnerships at the heart of global health advancement" will be held on 19 - 20 May 2023 at the Maison Internationale des Associations (MIA) in Geneva, Switzerland as a hybrid event.

International Generic and Biosimilar Medicines Association [IGBA]
https://www.igbamedicines.org/
News
No new digest announcements identified

PhRMA  [to 06 May 2023]
http://www.phrma.org/
Press Releases
PhRMA Statement on FDA Draft Guidance on Clinical Trials
WASHINGTON, D.C. (May 2, 2023) – The Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President, Science and Regulatory Advocacy Lucy Vereshchagina, PhD, released a statement on the U.S. Food and Drug Administration’s (FDA)’s release of the draft guidance on decentralized clinical trials.

PhRMA Files Amicus Brief with the U.S. Court of Appeals for the Fifth Circuit in Support of FDA
May 1, 2023
Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) filed an amicus brief alongside other leading industry stakeholders in

Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

AstraZeneca
Press Releases - No new digest announcements identified

Bharat Biotech
Press Releases - No new digest announcements identified

BioCubaFarma – Cuba
Últimas Noticias - Website not responding at inquiry

Biological E
News - No new digest announcements identified

BioNTech
Press Releases - No new digest announcements identified
Boehringer
Press Releases - No new digest announcements identified

CanSinoBIO
News - Website not responding at inquiry

CIGB
Latest News - No new digest announcements identified

Cinagen
Recent News - No new digest announcements identified

Clover Biopharmaceuticals - China
News - No new digest announcements identified

Curevac [Bayer Ag – Germany]
News - No new digest announcements identified

Gamaleya National Center
Latest News and Events - See Russia above.

GSK
Press releases for media
03 May 2023
US FDA approves GSK’s Arexvy, the world’s first respiratory syncytial virus (RSV) vaccine for older adults
- Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time
- The approval is based on data from the positive pivotal AReSVi-006 phase III trial that showed exceptional efficacy in older adults, including those with underlying medical conditions, and in those with severe RSV disease
- US launch is planned before the 2023/24 RSV season

IMBCAMS, China
Home - Website not responding at inquiry

Janssen/JNJ
Press Releases
May 02, 2023  United States
Janssen Enters Worldwide Collaboration and License Agreement with Cellular Biomedicine Group to Develop Next Generation CAR-T Therapies
Agreement Deepens Janssen’s Leadership in Oncology and Hematology, and Accelerates Commitment to Delivering Transformational Cell Therapies

Merck
News releases - No new digest announcements identified

Moderna
**Press Releases**

02 May, 2023

**Moderna Announces Establishment of an Enterprise Solutions Hub and Commercial Operations in The Philippines**

The Enterprise Solutions Hub in the Philippines will support the Asia Pacific region and complements Moderna’s Enterprise Solutions Hubs in Warsaw, Poland, and Atlanta, U.S.

**Nanogen**

*News* - No new digest announcements identified

**Novartis**

*News* - No new digest announcements identified

**Novavax**

*Press Releases* - No new digest announcements identified

**Pfizer**

*Recent Press Releases* - No new digest announcements identified

**R-Pharm**

https://rpharm-us.com/index.php

[No news or media page identified]

**Sanofi Pasteur**

*Press Releases* - No new digest announcements identified

**Serum Institute of India**

*NEWS & ANNOUNCEMENTS* - No new digest announcements identified

**Sinopharm/WIBPBIBP**

*News* - No new digest announcements identified

**Sinovac**

*Press Releases* - No new digest announcements identified

**SK Biosciences**

*Press Releases* - No new digest announcements identified

**Takeda**

*Newsroom* - No new digest announcements identified

**Valneva**

*Press Releases*

March 30, 2023

**Valneva to Present on its Chikungunya Vaccine Candidate and Host a Roundtable at the 23rd World Vaccine Congress in Washington D.C.**

**Vector State Research Centre of Viralogy and Biotechnology**
Journal Watch

*Vaccines and Global Health: The Week in Review* continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

**AJOB Empirical Bioethics**
Volume 14, 2023 Issue 1
https://www.tandfonline.com/toc/uabr21/current
[Reviewed earlier]

**AMA Journal of Ethics**
Volume 25, Number 5: E305-379 May 2023
https://journalofethics.ama-assn.org/issue/ipe-and-innovation

**IPE and Innovation**
Interprofessional education (IPE) began as a health and social care movement in the early 1970s and took firm hold in US-based accreditation standards in the mid-2000s. IPE should start early in health professions education and prepare clinicians for cross-disciplinary work culture that nourishes quality, collegiality, and safety in a rapidly evolving health sector. Since formation of the Interprofessional Education Collaborative®, IPE trends have gained momentum. This theme issue considers strategies
for wider implementation of educational innovations that promote patient-centered and collaborative care, reduce iatrogenic harm, and improve health outcomes.

**American Journal of Infection Control**  
May 2023  Volume 51  Issue 5  p481-602  
http://www.ajicjournal.org/current  
*State of the Science Review*  
**Is it safe and effective to administer COVID-19 vaccines during pregnancy? A systematic review and meta-analysis**  
Ishaque Hameed, et al.  
Published online: August 22, 2022  
p582-593

**American Journal of Preventive Medicine**  
May 2023  Volume 64  Issue 5  p611-780  
http://www.ajicjournal.org/current  
*Research Briefs*  
**Characteristics of the Moveable Middle: Opportunities Among Adults Open to COVID-19 Vaccination**  
Amel Omari, et al.  
Published online: December 20, 2022  
p734-741

**American Journal of Public Health**  
May 2023  113(5)  
http://ajph.aphapublications.org/toc/ajph/current  
*BOOKS & MEDIA*  
**Smallpox Immunization in Colonial America: All Too Relevant Today**  
Prevention, Immunization/Vaccines, History, Health Policy, Epidemiology  
Tara C. Smith

*NOTES FROM THE FIELD*  
**Engaging the Poultry Industry to Vaccinate Vulnerable Populations, Arkansas, 2021–2022**  
Health Service Delivery, Occupational Health, Immunization/Vaccines, COVID-19, Race/Ethnicity, Asians, Notes From the Field, Access to Care  
Austin Porter, Pansy James and Cassie Cochran  
113(5), pp. 500–503

**Mpox Vaccine Interest Survey Prioritization and Data Flow: Maricopa County, Arizona, July–August 2022**  
Infections, Prevention, Lesbian/Gay/Bisexual/Transgender Persons, Public Health Practice, Other Infections, Epidemiology, Notes From the Field  
Brandon J. Howard, Jennifer E. Collins, R. Nicholas Staab, Sonia Singh, Erika Lara, Melissa Kretscher, Lori Rehder, Anne Dellos, Jessica R. White and Ariella P. Dale  
113(5), pp. 504–508
American Journal of Tropical Medicine and Hygiene
https://www.ajtmh.org/view/journals/tpmd/108/5/tpmd.108.issue-5.xml

Articles

**Development of a Scorecard to Monitor Progress toward National Cholera Elimination: Its Application in Uganda**
Godfrey Bwire, et al.
Volume/Issue: Volume 108: Issue 5
Article Category: Research Article
DOI: https://doi.org/10.4269/ajtmh.23-0007

Annals of Internal Medicine
April 2023 Volume 176, Issue 4
http://annals.org/aim/issue
[Reviewed earlier]

Artificial Intelligence – An International Journal
Volume 318 May 2023
[New issue; No digest content identified]

BMC Cost Effectiveness and Resource Allocation
http://resource-allocation.biomedcentral.com/
(Accessed 06 May 2023)
[No new digest content identified]

BMJ Global Health
April 2023 - Volume 8 - 4
https://gh.bmj.com/content/8/4
[Reviewed earlier]

BMC Health Services Research
http://www.biomedcentral.com/bmchealthservres/content
(Accessed 06 May 2023)
**Drug shortages in China: a cross-sectional study**

*Drug shortages significantly threaten public health and medical service provision worldwide. Research evidence on the complete picture of drug shortages is currently scant in China. This study aimed to provide...*

Authors: Yinyin Song, Jianchun Li, Fei Zhao and Pengfei Jin
Citation: BMC Health Services Research 2023 23:438
Content type: Research Published on: 4 May 2023
Supporting US healthcare providers for successful vaccine communication
While many healthcare providers (HCPs) have navigated patients' vaccine concerns and questions prior to the rollout of the COVID-19 vaccines, sentiments surrounding the COVID-19 vaccines have presented new and...
Authors: Amanda J Pierz, Lauren Rauh, Dima Masoud, Alanna Kate Cruz, P. Christopher Palmedo, Scott C Ratzan and Ruth Parker
Citation: BMC Health Services Research 2023 23:423
Content type: Research Published on: 2 May 2023

BMC Infectious Diseases
http://www.biomedcentral.com/bmicinfectdis/content
(Accessed 06 May 2023)
[No new digest content identified]

BMC Medical Ethics
http://www.biomedcentral.com/bmcmedethics/content
(Accessed 06 May 2023)
[No new digest content identified]

BMC Medicine
http://www.biomedcentral.com/bmcmed/content
(Accessed 06 May 2023)
[No new digest content identified]

BMC Pregnancy and Childbirth
http://www.biomedcentral.com/bmcpregnancychildbirth/content
(Accessed 06 May 2023)
[No new digest content identified]

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
( Accessed 06 May 2023)
Complete childhood vaccination and associated factors among children aged 12–23 months in Dabat demographic and health survey site, Ethiopia, 2022
Childhood immunization is one of the most cost-effective public health strategies to prevent children’s mortality and morbidity from infectious diseases, but the Covid-19 pandemic and associated disruptions ha...
Authors: Abebaw Addis Gelagay, Abebaw Gebeeyehu Worku, Debrework Tesgera Bashah, Nigusie Birhan Tebeje, Mignote Hailu Gebrie, Hedija Yenus Yeshita, Endeshaw Adimasu Cherkose, Birhanu Abera Ayana, Ayenew Molla Lakew, Desalegn Anmut Bitew, Desale Bihonegn Asmamaw, Wubshet Debebe Negash, Tadele Biresaw Belachew and Elsa Awoke Fentie
Citation: BMC Public Health 2023 23:802
BMC Research Notes
http://www.biomedcentral.com/bmcresnotes/content
(Accessed 06 May 2023)
[No new digest content identified]

BMJ Evidence-Based Medicine
April 2023 - Volume 28 - 2
https://ebm.bmj.com/content/28/2
[Reviewed earlier]

BMJ Open
May 2023 - Volume 13 - 5
https://bmjopen.bmj.com/content/13/1
[Reviewed earlier]

Bulletin of the Atomic Scientists
March 2023
https://thebulletin.org/magazine/2023-03/
[Reviewed earlier]

Bulletin of the World Health Organization
Volume 101(5); 2023 May 1
https://www.ncbi.nlm.nih.gov/pmc/issues/434533/
Editorials

WHO's health inequality data repository
Ahmad Reza Hosseinpoor, Nicole Bergen, Katherine Kirkby, Anne Schlotheuber, Daniel A Antiporta, Stephen Mac Feely
Bull World Health Organ. 2023 May 1; 101(5): 298–298A. Published online 2023 May 1.
doi: 10.2471/BLT.23.290004
PMCID: PMC10140685

Building an economy for health for all: a call for papers
Ritu Sadana, Rajat Khosla, Rachel Gisselquist, Kunal Sen
Bull World Health Organ. 2023 May 1; 101(5): 299–299A. Published online 2023 May 1.
doi: 10.2471/BLT.23.290078
PMCID: PMC10140695

Emergency committee recommendations on mpox – what’s next?
Rosamund F Lewis, Krutika Kuppalii, Ana Hoxha, Meg C Doherty, on behalf of WHO mpox response incident management team
Policy & Practice

**WHO target product profiles to shape global research and development**
Sarah C Charnaud, Vasee Moorthy, John Reeder, Anna Laura Ross
doi: 10.2471/BLT.22.289521
PMCID: PMC10140686

**Poliovirus surveillance in patients with primary immunodeficiencies, India**
Madhu Chhanda Mohanty, Ahmad Mohammad, Harish Verma, Arun Kumar, Manisha Ranjan Madkaikar, Mukesh Desai, Swapnil Yashwant Varose, Unnati Sawant, Reetika Malik Yadav, Prasad Taur, Rachana Kathuria, Manogat Tatkare, Megh Murhekar, Pradeep Haldar, Priya Abraham
doi: 10.2471/BLT.22.289066
PMCID: PMC10140681

**Perspectives**

**Collaborations between product development partnerships and the World Health Organization**
Matthias Helble, Tanja Kuchenmüller, John Reeder, Jerome H Kim, Bernard Pécout, David Reddy, Mel Spigelman, Soumya Swaminathan
doi: 10.2471/BLT.22.289154
PMCID: PMC10140690

Cell
Apr 27, 2023  Volume 186  Issue 9  p1817-2040
https://www.cell.com/cell/current
[New issue; No digest content identified]

Child Care, Health and Development
Volume 49, Issue 3  Pages: 407-616  May 2023
https://onlinelibrary.wiley.com/toc/13652214/current
[Reviewed earlier]

Clinical Pharmacology & Therapeutics
Volume 113, Issue 5  Pages: 935-1161  May 2023
https://ascpt.onlinelibrary.wiley.com/toc/15326535/current
Research Articles
Generating the Right Evidence at the Right Time: Principles of a New Class of Flexible Augmented Clinical Trial Designs
Clinical Therapeutics
March 2023 Volume 45 Issue 3 p195-302
http://www.clinicaltherapeutics.com/current
[Reviewed earlier]

Clinical Trials
Volume 20 Issue 2, April 2023
https://journals.sagepub.com/toc/ctja/20/2
[Reviewed earlier]

Conflict and Health
http://www.conflictandhealth.com/
[Accessed 06 May 2023]
[No new digest content identified]

Contemporary Clinical Trials
Volume 127 April 2023
[New issue; No digest content identified]

The CRISPR Journal
Volume 6, Issue 2 / April 2023
https://www.liebertpub.com/toc/crispr/6/2
[Reviewed earlier]

Current Genetic Medicine Reports
Volume 10, issue 3, September 2022
https://link.springer.com/journal/40142/volumes-and-issues/10-3
[Reviewed earlier]

Current Medical Research and Opinion
Volume 39, Issue 4 2023
https://www.tandfonline.com/toc/icmo20/current
[Reviewed earlier]

Current Opinion in Infectious Diseases
April 2023 - Volume 36 - Issue 2
https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx
[Reviewed earlier]

Current Protocols in Human Genetics
Volume 108, Issue 1  December 2020
https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current
[Reviewed earlier]

Developing World Bioethics
Volume 23, Issue 1  Pages: 1-87  March 2023
https://onlinelibrary.wiley.com/toc/14718847/current
[Reviewed earlier]

Development in Practice
Volume 33, Issue 3, 2023
http://www.tandfonline.com/toc/cdip20/current
[Reviewed earlier]

Development Policy Review
Volume 41, Issue 3  May 2023
https://onlinelibrary.wiley.com/toc/14677679/current

ARTICLES
Nutrition-sensitive lockdowns: Conceptual framework and empirical insights from Africa during COVID-19
Thomas Daum, Hans Konrad Biesalski, Nikola Blaschke, Christine Bosch, Denise Güttler, Jakob Heni, Juliet Kariuki, Roseline Katusiime, Anna Seidel, Zinsou-Narcisse Senon, George Woode, Regina Birner
e12666
First Published: 13 September 2022

Disaster Medicine and Public Health Preparedness
Volume 16 - Issue 6 - December 2022
https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue
[Reviewed earlier]

Disasters
Volume 47, Issue 2  Pages: 245-542  April 2023
https://onlinelibrary.wiley.com/toc/14677717/2023/47/2
[Reviewed earlier]
Use of High-Resolution Geospatial and Genomic Data to Characterize Recent Tuberculosis Transmission, Botswana

C. R. Baker et al.
**Expert Review of Vaccines**  
Vol 22 (1) 2023  Issue In Progress  
https://www.tandfonline.com/toc/ierv20/current  
[Reviewed earlier]  

**Foreign Affairs**  
May/June 2023  Volume 102, Number 3  
https://www.foreignaffairs.com/issues/2023/102/3  
[New issue; No digest content identified]  

**Forum for Development Studies**  
Volume 50, 2023 - Issue 2  
http://www.tandfonline.com/toc/sfds20/current  
[New issue; No digest content identified]  

**Genetics in Medicines**  
Volume 25, Issue 5  May 2023  
ACMG Statements  
Points to consider in the practice of postmortem genetic testing: A statement of the American College of Medical Genetics and Genomics (ACMG)  
Joshua L. Deignan, Mauricio De Castro, Vanessa L. Horner, Tami Johnston, ... Marwan K. Tayeh  
Article 100017  

The clinical application of polygenic risk scores: A points to consider statement of the American College of Medical Genetics and Genomics (ACMG)  
Aya Abu-El-Haija, Honey V. Reddi, Hannah Wand, Nancy C. Rose, ... Michael F. Murray  
Article 100803  

**Genome Medicine**  
https://genomemedicine.biomedcentral.com/articles  
[Accessed 06 May 2023]  
[No new digest content identified]  

**Global Health Action**  
Volume 16, Issue 1 (2023)  
https://www.tandfonline.com/toc/zgha20/current?nav=tocList  
[Reviewed earlier]
Global Legal Monitor – Library of Congress/USA
https://www.loc.gov/collections/global-legal-monitor/
[Accessed 06 May 2023]

Article
Italy: Constitutional Court Declares Provision on Compensation for Vaccine Injuries Unconstitutional

On February 9, 2023, the Constitutional Court of Italy issued Decision No. 35 (the Decision) declaring the unconstitutionality of article 3, paragraph 1 of Law No. 210 of February 25, 1992, concerning Compensation for Injuries Caused by Irreversible Complications due to Compulsory Vaccinations, Transfusions, and Administration of Blood Products.

Background to the Decision
The Italian Constitutional Court was called to decide on the constitutionality of article 3, paragraph 1 of Law No. 210 in a case pending between the Ministry of Health and the legal representatives of a minor...

In particular, the constitutional question referred to the challenged provision’s restriction of the statutory period for the calculation of compensation for injuries arising from forced vaccination of patients to three years, counted from the moment when the plaintiff became aware of the injury. (No. 1, para. 2.) Hence, the Constitutional Court was requested to decide whether the plaintiff had a right to obtain compensation in its entirety — that is, without the limit of the prior three-year period. (No. 1.1.)

Contributor: Figueroa, Dante
Date: 2023-04-24

Globalization and Health
http://www.globalizationandhealth.com/
[Accessed 06 May 2023]
[No new digest content identified]
...The papers in this special section work together to move toward a global social medicine for the 22nd century. They envision a global social medicine that confronts and moves beyond the traditionally colonial, xenophobic, heteronormative, patriarchal, gender-binary-bound, capitalist, and racist histories of the fields of global health and human rights. They seek to instantiate a global social medicine that centers knowledge and experiences from the Global South and works toward social justice and health equity at scale. In this special section, the authors are particularly interested in understanding, challenging, and expanding our perspectives and enactments of the right to health. Unlike neoliberal perspectives on health that often limit their explanatory capacity to how individuals behave in the world, the papers here move beyond the focus on lifestyles and on the phantasmagoria of a sovereign subject with supposedly free agency. Instead, authors work toward critical consciousness that accounts for structural processes—with their inequities and disruptions, as well as their effects on individuals—and how this consciousness can open new horizons for collective transformation and social emancipation in health...

Health Economics, Policy and Law
Volume 18 - Issue 2 - April 2023
https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue
[Reviewed earlier]

Health Policy and Planning
Volume 38, Issue 3, April 2023
https://academic.oup.com/heapol/issue/38/3
ORIGINAL ARTICLES
[Reviewed earlier]

Health Research Policy and Systems
http://www.health-policy-systems.com/content
[Accessed 06 May 2023]
[No new digest content identified]

Human Gene Therapy
Volume 34, Issue 7-8 / April 2023
https://www.liebertpub.com/toc/hum/34/7-8
[Reviewed earlier]

Humanitarian Practice Network
https://odzihn.org/
Featured Publications
[No new digest content identified]

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 18, Issue 5, 2022
Immunity
Apr 11, 2023 Volume 56 Issue 4 p687-892
https://www.cell.com/immunity/current
[Reviewed earlier]

Infectious Agents and Cancer
http://www.infectagentscancer.com/
[Accessed 06 May 2023]
[No new digest content identified]

Infectious Diseases of Poverty
http://www.idpjournal.com/content
[Accessed 06 May 2023]
[No new digest content identified]

International Health
Volume 15, Issue 3, May 2023
https://academic.oup.com/inthealth/issue/15/3
[New issue; No digest content identified]

International Human Rights Law Review
Volume 11 (2022): Issue 2 (Dec 2022)
https://brill.com/view/journals/hrlr/11/2/hrlr.11.issue-2.xml
Table of Contents
[Reviewed earlier]

International Journal of Community Medicine and Public Health
Vol. 10 No. 3 (2023): March 2023
[Reviewed earlier]

International Journal of Epidemiology
Volume 52, Issue 2, April 2023
https://academic.oup.com/ije/issue
[Reviewed earlier]

International Journal of Human Rights in Healthcare
This Viewpoint from the president of the National Academy of Medicine looks back at the academy's accomplishments and looks forward to the possibilities it hopes to achieve to better medicine and society.

Optimizing US Global Health Funding
Anand Parekh, MD, MPH
This Viewpoint recommends increasing US global health funding levels, outlines steps for ensuring optimal integration and coordination of activities, and discusses ways to elevate noncommunicable diseases.

Editorial
Screening for Latent Tuberculosis Infection Among Non–US-Born Adults in the USA Path Toward Elimination
Priya B. Shete, MD, MPH; Amy S. Tang, MD; Jennifer Flood, MD, MPH
has audio
Audio: USPSTF Recommendation: Screening for Latent Tuberculosis Infection in Adults
Editorial
Screening for Latent Tuberculosis Infection
Dick Menzies, MD

JAMA Health Forum
May 2023, Vol 4, No. 5
https://jamanetwork.com/journals/jama-health-forum/issue
JAMA Forum
Human Reactions to Public Health Interventions—Implications for Evaluation and Well-being
Sherry Glied, PhD, MA
open access
This JAMA Forum discusses the public health community’s reaction to a recent Cochrane Collaboration review on whether face masks and other physical public health interventions reduced the
spread of the COVID-19 and provides counterarguments to the review’s findings that these interventions did not help.

**JAMA Pediatrics**
April 2023, Vol 177, No. 4, Pages 327-441
https://jamanetwork.com/journals/jamapediatrics/currentissue
[Reviewed earlier]

**JBI Evidence Synthesis**
April 2023 - Volume 21 - Issue 4
https://journals.lww.com/jbisrir/Pages/currenttoc.aspx
[New issue; No digest content identified]

**Journal of Adolescent Health**
April 2023 Volume 72 Issue 4 p485-646
https://www.jahonline.org/current
[Reviewed earlier]

**Journal of Artificial Intelligence Research**
Vol. 76 (2023)
https://www.jair.org/index.php/jair
Contents
[Reviewed earlier]

**Journal of Community Health**
Volume 48, issue 2, April 2023
[Reviewed earlier]

**Journal of Current Medical Research and Opinion**
...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.
March 8, 2023  Vol 6, No 03 (2023)
https://www.cmro.in/index.php/jcmro/issue/view/65
[Reviewed earlier]

**Journal of Development Economics**
Volume 162  May 2023
[Reviewed earlier]
Journal of Empirical Research on Human Research Ethics
Volume 18 Issue 1-2, February-April 2023
http://journals.sagepub.com/toc/jre/current
[Reviewed earlier]

Journal of Epidemiology & Community Health
April 2023 - Volume 77 - 4
https://jech.bmj.com/content/77/4
[Reviewed earlier]

Journal of Evidence-Based Medicine
Volume 16, Issue 1 Pages: 1-100 March 2023
https://onlinelibrary.wiley.com/toc/17565391/current
[Reviewed earlier]

Journal of Global Ethics
Volume 19, Issue 1 (2023)
http://www.tandfonline.com/toc/rjge20/current
[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)
Volume 34, Number 2, May 2023
https://muse.jhu.edu/issue/50186
Table of Contents
[Reviewed earlier]

Journal of Immigrant and Minority Health
Volume 25, issue 2, April 2023
Contents
[Reviewed earlier]

Journal of Immigrant & Refugee Studies
Volume 21, 2023, Issue 2
https://www.tandfonline.com/toc/wimm20/current
[Reviewed earlier]

Journal of Infectious Diseases
Volume 227, Issue 7, 1 April 2023
Beyond regulatory approaches to ethics: making space for ethical preparedness in healthcare research

Kate Lyle, Susie Weller, Gabby Samuel, Anneke M Lucassen

Abstract

Centralised, compliance-focused approaches to research ethics have been normalised in practice. In this paper, we argue that the dominance of such systems has been driven by neoliberal approaches to governance, where the focus on controlling and individualising risk has led to an overemphasis of decontextualised ethical principles and the conflation of ethical requirements with the documentation of ‘informed consent’. Using a UK-based case study, involving a point-of-care-genetic test as an illustration, we argue that rather than ensuring ethical practice such compliance-focused approaches may obstruct valuable research. We call for an approach that encourages researchers and research communities—including regulators, ethics committees, funders and publishers of academic research—to acquire skills to make morally appropriate decisions, and not base decision-making solely on compliance with prescriptive regulations. We call this ‘ethical preparedness’ and outline how a research ethics system might make space for this approach.

Towards a new model of global health justice: the case of COVID-19 vaccines

Nancy S Jecker, Caesar A Atuire, Susan J Bull
Journal of Pharmaceutical Policy and Practice
https://joppp.biomedcentral.com/
[Accessed 06 May 2023]
[No new digest content identified]

Journal of Public Health Management & Practice
May/June 2023 - Volume 29 - Issue 3
https://journals.lww.com/jphmp/pages/currenttoc.aspx
[Reviewed earlier]

Journal of Public Health Policy
Volume 44, issue 1, March 2023
https://link.springer.com/journal/41271/volumes-and-issues/44-1
Articles
[Reviewed earlier]

Journal of Refugee & Global Health
Volume 4, Issue 1 (2021)
https://ir.library.louisville.edu/rgh/
[Reviewed earlier]

Journal of the Royal Society – Interface
May 2023  Volume 20  Issue 202
https://royalsocietypublishing.org/toc/rsif/current
[Reviewed earlier]

Journal of Travel Medicine
Volume 30, Issue 2, March 2023
https://academic.oup.com/jtm/issue
[Reviewed earlier]

Journal of Virology
Volume 97  Number 3  March 2023
http://jvi.asm.org/content/current
[Reviewed earlier]

The Lancet
May 06, 2023  Volume 401  Number 10387  p1473-1544
https://www.thelancet.com/journals/lancet/issue/current
Editorial
India's ascendency: leadership demands integrity
The Lancet

The Lancet Child & Adolescent Health
Apr 2023 Volume 7 Number 4 p223-296, e10
https://www.thelancet.com/journals/lanchi/issue/current
[Reviewed earlier]

Lancet Digital Health
Apr 2023 Volume 5 Number 4 e174-e247
https://www.thelancet.com/journals/landig/issue/current
[Reviewed earlier]

Lancet Global Health
May 2023 Volume 11 Number 5 e629-e795
https://www.thelancet.com/journals/langlo/issue/current
[Reviewed earlier]

Lancet Infectious Diseases
Apr 2023 Volume 23 Number 4 p381-508, e121-e165
https://www.thelancet.com/journals/laninf/issue/current
[Reviewed earlier]

Lancet Public Health
Apr 2023 Volume 8 Number 4 e247-e317
https://www.thelancet.com/journals/lanpub/issue/current
[Reviewed earlier]

Lancet Respiratory Medicine
Apr 2023 Volume 11 Number 4 p297-390, e31-e40
https://www.thelancet.com/journals/lanres/issue/current
[Reviewed earlier]

Maternal and Child Health Journal
Volume 27, issue 5, May 2023
[New issue; No digest content identified]

Medical Decision Making (MDM)
Volume 43 Issue 4, May 2023
The Milbank Quarterly
*A Multidisciplinary Journal of Population Health and Health Policy*
Volume 101, Issue S1 Pages: 1-892 April 2023
https://onlinelibrary.wiley.com/toc/14680009/current
*Special Centennial Issue: The Future of Population Health: Challenges & Opportunities*
[Reviewed earlier]

Nature
Volume 617 Issue 7959, 4 May 2023
https://www.nature.com/nature/volumes/616/issues/7959
[New issue; No digest content identified]

Nature Biotechnology
Volume 41 Issue 4, April 2023
https://www.nature.com/nbt/volumes/41/issues/4
[Reviewed earlier]

Nature Communications
https://www.nature.com/subjects/health-sciences/ncomms
(Accessed 06 May 2023)
[No new digest content identified]

Nature Genetics
Volume 55 Issue 4, April 2023
https://www.nature.com/ng/volumes/55/issues/4
[Reviewed earlier]

Nature Human Behaviour
Volume 7 Issue 4, April 2023
https://www.nature.com/nathumbehav/volumes/7/issues/4
[Reviewed earlier]

Nature Medicine
Volume 29 Issue 4, April 2023
https://www.nature.com/nm/volumes/29/issues/4
[Reviewed earlier]
**Nature Reviews Drug Discovery**
Volume 22 Issue 4, April 2023
https://www.nature.com/nrd/volumes/22/issues/4
[Reviewed earlier]

**Nature Reviews Genetics**
Volume 24 Issue 4, April 2023
https://www.nature.com/nrg/volumes/24/issues/4
[Reviewed earlier]

**Nature Reviews Immunology**
Volume 23 Issue 4, April 2023
https://www.nature.com/nri/volumes/23/issues/4
[Reviewed earlier]

**New England Journal of Medicine**
May 4, 2023 Vol. 388 No. 18
https://www.nejm.org/toc/nejm/medical-journal
Perspective
*Combating West Nile Virus Disease — Time to Revisit Vaccination*

**npj Vaccines**
https://www.nature.com/npjvaccines/
[Accessed 06 May 2023]
[No new digest content identified]

**Pediatrics**
Volume 151, Issue 5 May 2023
https://publications.aap.org/pediatrics/issue/151/5
Articles
*Effectiveness of BNT162b2 COVID-19 Vaccination in Children and Adolescents*
Nicola P. Klein, MD, PhD; Maria Demarco, PhD; Katherine E. Fleming-Dutra, MD; Melissa S. Stockwell, MD, MPH; Anupam B. Kharbanda, MD, MSc ...

*COVID-19 Vaccine Safety First Year Findings in Adolescents*
Elisabeth M. Hesse, MD, MTM&H; Anne Hause, PhD, MSPH; Tanya Myers, PhD, MSc; John R. Su, MD, PhD, MPH; Paige Marquez, MSPH ...

*Role of Parents’ Perceived Risk and Responsibility in Deciding on Children’s COVID-19 Vaccination*
Ying Liu, PhD; Wändi Bruine de Buin, PhD; Arie Kapteyn, PhD; Peter G. Szilagyi, MD, MPH
Review Articles

**Provider-Based HPV Vaccine Promotion Interventions: A Meta-analysis**
Chi-Fang Wu, PhD; Linda Highfield, PhD; John M. Swint, PhD; David R. Lairson, PhD

Special Articles

**Achieving Elimination of Perinatal HIV in the United States**
Margaret A. Lampe, RN, MPH; Steven R. Nesheim, MD; Keydra L. Oladapo, MS; Alexander C. Ewing, MPH; Jeffrey Wiener, PhD.

PharmacoEconomics
Volume 41, issue 5, May 2023
[Reviewed earlier]

PLoS Biology
https://journals.plos.org/plosbiology/
(Accessed 06 May 2023)
[No new digest content identified]

PLoS Genetics
https://journals.plos.org/plosgenetics/
(Accessed 06 May 2023)
[No new digest content identified]

PLOS Global Public Health
https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60
(Accessed 06 May 2023)

**Optimizing next-generation RSV prevention in Mali: A cost-effectiveness analysis of pediatric vaccination, maternal vaccination, and extended half-life monoclonal antibody immunoprophylaxis**
Rachel S. Laufer, Ranju Baral, Andrea G. Buchwald, James D. Campbell, Flanon Coulibaly, Fatoumata Diallo, Moussa Doumbia, Amanda J. Driscoll, Alison P. Galvani, Adama M. Keita, Kathleen M. Neuzil, Samba Sow, Clint Pecenka, Justin R. Ortiz, Meagan C. Fitzpatrick
Research Article | published 05 May 2023 PLOS Global Public Health
https://doi.org/10.1371/journal.pgph.0001432

**Knowledge, attitudes, and practices regarding immunity boosting dietary behavior of mass population amid COVID-19**
Mehedy Hasan Abir, Mahdi Al Hasan Rahat, Silvia Naznin Etu, Tahmid Hussain, Anik Chakraborty, Mahabub Alam, Emily Litzow, Mohammad Mahmudul Hassan
Research Article | published 03 May 2023 PLOS Global Public Health
https://doi.org/10.1371/journal.pgph.0001872
**Abstract**

Experimental Human Pneumococcal Challenge (EHPC) involves the controlled exposure of adults to a specific antibiotic-sensitive Streptococcus pneumoniae serotype, to induce nasopharyngeal colonisation for the purpose of vaccine research. The aims are to review comprehensively the safety profile of EHPC, explore the association between pneumococcal colonisation and frequency of safety review and describe the medical intervention required to undertake such studies.

**Methods**

A single-centre review of all EHPC studies performed 2011–2021. All recorded serious adverse events (SAE) in eligible studies are reported. An unblinded meta-analysis of collated anonymised individual patient data from eligible EHPC studies was undertaken to assess the association between experimental pneumococcal colonisation and the frequency of safety events following inoculation.
Results
In 1416 individuals (median age 21, IQR 20–25), 1663 experimental pneumococcal inoculations were performed. No pneumococcal-related SAE have occurred. 214 safety review events were identified with 182 (12.85%) participants presenting with symptoms potentially in keeping with pneumococcal infection, predominantly in pneumococcal colonised individuals (colonised = 96/658, non-colonised = 86/1005, OR 1.81 (95% CI 1.28–2.56, P = <0.001). The majority were mild (pneumococcal group = 72.7% [120/165 reported symptoms], non-pneumococcal = 86.7% [124/143 reported symptoms]). 1.6% (23/1416) required antibiotics for safety.

Discussion
No SAEs were identified directly relating to pneumococcal inoculation. Safety review for symptoms was infrequent but occurred more in experimentally colonised participants. Most symptoms were mild and resolved with conservative management. A small minority required antibiotics, notably those serotype 3 inoculated.

Conclusion
Outpatient human pneumococcal challenge can be conducted safely with appropriate levels of safety monitoring procedures in place.

PLoS Pathogens
http://journals.plos.org/plospathogens/
[Accessed 06 May 2023]
[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States
May 2, 2023 vol. 120 no. 18
https://www.pnas.org/toc/pnas/120/1
Opinion
April 27, 2023
Urban malaria may be spreading via the wind—here’s why that’s important
T. Lehmann, R. Bamou, [....] Y.-M. Linton
Malaria remains the most important vector-borne disease in Africa, with over 590,000 deaths annually (1). Although until now, malaria in Africa has been primarily a rural problem, the recent establishment and expansion of the invasive urban Asian vector Anopheles stephensi will likely drastically change Africa’s disease risk landscape. Urban malaria will become a bigger threat (2–6). Unlike all other African malaria vectors, An. stephensi larvae thrive in container habitats (e.g., abandoned tires or cisterns) near human dwellings, similar to the urban yellow fever mosquito, Aedes aegypti. Thus, human populations in the continent’s rapidly expanding megacities, such as Kinshasa and Lagos, and metropolises, such as Khartoum and Abidjan, are now more vulnerable to malaria (2, 3, 5, 6)...

PNAS Nexus
Volume 2, Issue 4, April 2023
https://academic.oup.com/pnasnexus/issue
[Reviewed earlier]
Prehospital & Disaster Medicine
Volume 38 - Issue 2 - April 2023
https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue
[Reviewed earlier]

Preventive Medicine
Volume 169  April 2023
[Reviewed earlier]

Proceedings of the Royal Society B
26 April 2023  Volume 290  Issue 1997
https://royalsocietypublishing.org/toc/rspb/current
[Reviewed earlier]

Public Health
Volume 218  Pages 1-208 (May 2023)
Review article  Full text access
Key factors influencing paediatric COVID-19 vaccine hesitancy: a brief overview and Decision-making Trial and Evaluation Laboratory analysis
Y. Wang, X. Zhang
Pages 97-105

Research article  Full text access
Impact of the COVID-19 lockdown on routine childhood vaccination coverage rates in Catalonia (Spain): a public health register–based study
Montse Martínez-Marcos, Edurne Zabaleta-del-Olmo, Esperanza-Luisa Gómez-Durán, Anna Reñé-Reñé, Carmen Cabezas-Peña
Pages 68-74

Public Health Ethics
Volume 16, Issue 1, April 2023
http://phe.oxfordjournals.org/content/current
Original Articles
Approaching COVID-19 as an Environmental Ethical Problem: A Perspective from African Relational Animal Ethics
Munamato Chemhuru
Public Health Ethics, Volume 16, Issue 1, April 2023, Pages 53–63,
https://doi.org/10.1093/phe/phad007

Public Health Reports
Volume 138 Issue 2, March/April 2023
Qualitative Health Research
Volume 33 Issue 5, April 2023
https://journals.sagepub.com/toc/qhra/current
[New issue; No digest content identified]

Research Ethics
Volume 19 Issue 2, April 2023
http://journals.sagepub.com/toc/reab/current
[Reviewed earlier]

Reproductive Health
http://www.reproductive-health-journal.com/content
[Accessed 06 May 2023]
[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)
https://www.paho.org/journal/en
Selected Articles
[No new digest content identified]

Risk Analysis
Volume 43, Issue 5  Pages: 867-1091  May 2023
https://onlinelibrary.wiley.com/toc/15396924/current
[Reviewed earlier]

Risk Management and Healthcare Policy
[Accessed 06 May 2023]
Original Research
Levels and Associated Factors of Clients’ Satisfaction Toward Child Immunization at Grassroot Health Care Centers in Ho Chi Minh City, Vietnam
Truong LTT, Thai TT, Nguyen TV, Nguyen TQ, Le TAT, Le NH, Pham PTT, Huynh QNH
Published Date: 3 May 2023

Science
Volume 380| Issue 6644| 5 May 2023
https://www.science.org/toc/science/current
Introduction to Special Issue - Autoimmunity

This special issue surveys current progress in our understanding of autoimmunity and the regulation of immune tolerance. Recent work has elucidated how T cell tolerance is maintained in the periphery, how inborn errors of the innate immune system’s nucleic acid–sensing machinery can trigger autoimmune disease, how autoimmune disease genetics can inform the development of future therapies, and how autologous hematopoietic stem cell transplantation can “reset” the immune system and treat autoimmune disease.

Policy Forum
Cascading failures in COVID-19 vaccine equity
BY James V. Lavery, Rachael M. Porter, David G. Addiss
04 May 2023: 460-462
Ethical analysis should encompass upstream decisions and their downstream consequences

The “equity-deficit cascade”
Key decision points and equity challenges for the distribution of COVID-19 vaccines

<table>
<thead>
<tr>
<th>DECISION POINT</th>
<th>EQUITY CHALLENGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>PUBLIC POLICY</td>
<td></td>
</tr>
<tr>
<td>Intellectual property (IP) laws and regulations</td>
<td>• IP laws and regulations for licensing and transfer of technologies may not adequately reflect the equity interests of public investment in vaccine science and manufacturing</td>
</tr>
<tr>
<td></td>
<td>• Business interests of manufacturers may be in conflict with equitable vaccine distribution</td>
</tr>
<tr>
<td>Trade agreements and barriers</td>
<td>• Import tariffs may create barriers to equitable vaccine distribution</td>
</tr>
<tr>
<td></td>
<td>• Established trade agreements and conventions tend to consolidate vaccine distribution among high-income countries (HICs)</td>
</tr>
<tr>
<td></td>
<td>• Incentive structures discourage companies from using the World Trade Organization’s Trade-Related Aspects of Intellectual Property Rights (TRIPS) flexibilities to increase equitable vaccine distribution</td>
</tr>
<tr>
<td>National policies for vaccine procurement</td>
<td>• Advance purchase agreements between companies and HICs limit supply for global distribution</td>
</tr>
</tbody>
</table>

VACCINE DISCOVERY

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Investment in vaccine science and manufacturing</td>
<td>• Investments in vaccine research occur disproportionately in the Global North</td>
</tr>
<tr>
<td>Vaccine performance, e.g., efficacy, effectiveness, and adverse reactions</td>
<td>• Vaccine business models may not adequately reflect equity interests of public and nonprofit investors in vaccine science</td>
</tr>
<tr>
<td></td>
<td>• Methods for determining safety and efficacy of vaccines underrepresent important and potentially high-risk groups, such as people with complex comorbidities, pregnant women, and children</td>
</tr>
<tr>
<td></td>
<td>• Clinical trial results drive implementation decisions but do not adequately predict public health value</td>
</tr>
</tbody>
</table>
### VACCINE DEVELOPMENT

**Vaccine pipeline management**
- Vaccine product profiles—e.g., cold-chain requirements, mode of administration, dose regimens, cost, and pricing estimates—may not account for equity implications
- Vaccine business models may not adequately reflect equity interests of public and nonprofit investors in vaccine science

**Production and technical requirements to manufacture at scale**
- Vaccine manufacturing capacity is inadequate to meet global demand
- Existing manufacturing capacity is disproportionately located in the Global North
- Vaccine business models may not adequately reflect equity interests of public and nonprofit investors in vaccine manufacturing

### VACCINE DELIVERY

**Procurement and accessibility**
- Priority vaccine procurement for HICs limits available supply for low- and middle-income countries (LMICs)
- Priority by “preferred customer” and purchasing power inhibits distribution according to public health goals

**Global vaccine distribution governance mechanisms**
- Global distribution mechanisms must compete with HIC priority for vaccine purchasing, which creates a “two-tiered” system of vaccine distribution

**Supply chain**
- Capacity limits constrain the kinds and volumes of vaccines that can be distributed to LMICs

**Global COVID-19 epidemiology and disparities**
- Persons most at risk of infection, disease, and death may not be prioritized for vaccination

**Global public health and public health goals**
- Different public health goals may require different vaccine-distribution strategies
- Limited vaccine access among some groups may result in loss of vaccine efficacy more generally because of the proliferation of COVID-19 variants globally

**Allocation considerations**
- Vaccine distribution may not be informed by appropriate ethical principles or values
- Procedures used in vaccine allocation may not be fair
- There is limited transparency about the rationales and justifications for distribution decisions

**Last mile**
- Within-country distribution to vaccine delivery sites may favor more-densely-populated areas, which could lead to systematically missing more-vulnerable or marginalized groups
- Decisions about where and how much vaccine to distribute may be driven by political considerations rather than public health priority and epidemiological data

**Last inch**
- Lack of trust in health systems and interventions may be greatest among marginalized communities, increasing vaccine hesitancy and reducing vaccine uptake and coverage
- Expectations in LMICs of late and limited distribution of vaccines may create attitudes of resignation and suppress demand, especially among more-marginalized communities
...Equity Must Have Meaning
The stark gap between the pervasive rhetoric about equity and the dismal reality of the global vaccine distribution for severe acute respiratory coronavirus 2 (SARS-CoV-2) demands a collective reckoning. A robust explanatory analysis of the causes of vaccine inequity in the COVID-19 vaccine distribution system, and shortcomings in the ethical justifications necessary to support the pervasive claims of equity, represents a constructive first step forward for all stakeholders. It might help private vaccine manufacturers to identify opportunities for process, practice, and strategy improvements and innovations. It might also serve as a useful guide for advocates for global COVID-19 vaccine equity and help inform present deliberations for a more genuinely equitable and effective response to future pandemics.

Despite earnest efforts by scientists and others to advance distributive equity, invoking the concept of equity has little real meaning in the absence of a comprehensive understanding of the forces, structures, and decisions that give rise to inequity and the ethical reasoning that gives the term its normative weight. Expansive rhetoric and empty promises have surprising staying power. If we wish equity to have anything more than allegorical value, we must take the concept more seriously, beginning with a disciplined and deliberate examination of the equity-deficit cascade.

Science and Engineering Ethics
Volume 29, issue 3, June 2023
[Reviewed earlier]

Science Translational Medicine
Volume 15| Issue 694| 3 May 2023
https://www.science.org/toc/stm/current
[New issue; No digest content identified]

Scientific Reports
https://www.nature.com/srep/articles?type=article
Article  Open Access
Published: 05 May 2023
Evaluating COVID-19 vaccination intentions and vaccine hesitancy among parents of children with autism spectrum disorder
Mohamed Adil Shah Khoodooth, etc.
Abstract
As the global vaccination mass campaign against COVID-19 extended to children aged 5 to 11 years, some parents remained hesitant about their children being administered the vaccine despite data supporting its safety. Parent vaccine hesitancy (PVH) may have predisposed certain groups of children, particularly those with autism spectrum disorder (ASD), to COVID-19 when other neurotypical children would have been vaccinated. We investigated the current PVH in 243 parents of child with ASD...

Social Science & Medicine
Volume 322| April 2023
Ethical considerations and methodological uses of Facebook data in public health research: A systematic review
Hannah Stuart Lathan, Amy Kwan, Courtney Takats, Joshua P. Tanner, ... Heidi E. Jones
Article 115807

Systematic Reviews
https://systematicreviewsjournal.biomedcentral.com/articles
[Accessed 06 May 2023]
[No new digest content identified]

Theoretical Medicine and Bioethics
Volume 44, April 2023, Issue 2
Special Issue: Controversial Arguments in Bioethics

Travel Medicine and Infectious Diseases
Volume 52 March–April 2023
[Reviewed earlier]

Tropical Medicine & International Health
Volume 28, Issue 4 Pages: i-iv, 247-342 April 2023
https://onlinelibrary.wiley.com/toc/13653156/current
[Reviewed earlier]

Vaccine
Volume 41, Issue 16 Pages 2631-2728 (17 April 2023)
https://www.sciencedirect.com/journal/vaccine/vol/41/issue/16
Selected Content
Conference info  Abstract only
Challenges and opportunities in developing a Shigella-containing combination vaccine for children in low- and middle-income countries: Report of an expert convening
Mark S. Riddle, A. Louis Bourgeois, Allison Clifford, Suhi Jeon, ... William P. Hausdorff
Pages 2634-2644

Short communication  Full text access
The time is now for committed and comprehensive action to attain more broadly protective coronavirus vaccines: The coronavirus vaccines R&D roadmap
Margaret Hamburg, Gregory A. Poland
Pages 2645-2647

Research article  Open access
Differential coverage for vaccines in the expanded program on immunization (EPI) among children in rural Pakistan
Shahira Shahid, Sheraz Ahmed, Muhammad Farrukh Qazi, Rafey Ali, ... Muhammad Imran Nisar
Pages 2680-2689

Vaccines
https://www.mdpi.com/journal/vaccines
[Accessed 06 May 2023]

Factors Associated with Vaccine Refusal (Polio and Routine Immunization) in High-Risk Areas of Pakistan: A Matched Case-Control Study
Open Access Article by Sajid Bashir Soofi

Value in Health
May 2023 Volume 26 Issue 5 p617-790
https://www.valueinhealthjournal.com/current

ECONOMIC EVALUATION
Health and Economic Evaluation of Vaccination Against Pertussis in China: A 40-Year Analysis
Dan Wu, et al.
Published online: October 31, 2022
p666-675

SYSTEMATIC LITERATURE REVIEW
Comparisons in the Health and Economic Assessments of Using Quadrivalent Versus Trivalent Influenza Vaccines: A Systematic Literature Review
Clara R. Warmath, et al.
Published online: November 24, 2022
p768-779

Contents [click to move among sections]
:: Coronavirus [COVID-19]
:: Organization Announcements
:: Journal Watch
:: Pre-Print Servers

Pre-Print Servers
Gates Open Research
https://gatesopenresearch.org/browse/articles
Systematic review of diagnostic and prognostic host blood transcriptomic signatures of tuberculosis disease in people living with HIV [version 2; peer review: 2 approved]
Simon C Mendelsohn, Savannah Verhage, Humphrey Mulenga, Thomas J Scriba, Mark Hatherill
Peer Reviewers: Theresa Ryckman; Nagasuma Chandra

Funders
Fogarty International Center
South African Medical Research Council
Harry Crossley Foundation
LATEST VERSION PUBLISHED 05 May 2023

The economic costs of malaria in pregnancy: evidence from four sub-Saharan countries [version 2; peer review: 1 approved, 1 approved with reservations]
Laia Cirera, Charfudin Sacoor, Martin Meremikwu, Louise Ranaivo, Manu F. Manun’Ebo, Dachi Arikpo, Osvaldo Matavele, Victor Rafaralaly, Didier Ndombe, Clara Pons Duran, Maximo Ramirez, Francesco Ramponi, Raquel González, Christina Maly, Elaine Roman, Elisa Sicuri, Franco Pagnoni, Clara Menéndez
Peer Reviewers: Laetitia Duval; Ann Levin

Funders
Generalitat de Catalunya - CERCA Program
‘Centro de Excelencia Severo Ochoa 2019–2023’ Program
Jhpiego
UNITAID
LATEST VERSION PUBLISHED 05 May 2023

Systematic review: Safety of surgical male circumcision in context of HIV prevention public health programmes [version 2; peer review: 2 approved]
Kazuaki Jindai, Tim Farley, Quentin Awori, Anaëlia-Siya Temu, Fabian Ndenzako, Julia Samuelson
Peer Reviewers: Tigistu Adamu Ashengo and Zebedee Mwandi; Busisiwe Msimanga-Radebe

Funder
Bill and Melinda Gates Foundation
LATEST VERSION PUBLISHED 03 May 2023

Reemergence of Dengue Virus Serotype 3, Brazil, 2023
Silva e Silva, Matilde Contreras Mejia, Luciana Fe Goncalves, Regina Maria Figueiredo, Ana Cecilia Ribeiro Cruz, Bruno Tardelli Diniz Nunes, Mayra Marinho Presibella, Nelson F Q Marques, Irina Nastassja Riediger, Marcos Cesar Lima de Mendonca, Fernanda Bruycker-Nogueira, Patricia Carvalho de Sequeira, Ana Maria Bispo de Filippis, Paola Cristina Resende, Tulio Campos, Gabriel Luz Wallau, Tiago Graf, Edson Delatorre, Edgar Kopp, Andrea Morrison, Jorge L Munoz-Jordan, Gonzalo Bello medRxiv 2023.05.03.23288351; doi: https://doi.org/10.1101/2023.05.03.23288351

COVID-19 vaccination at a hospital in Paris: spatial analyses and inverse equity hypothesis
Valery Ridde, Gaele Andre, Olivier Bouchaud, Emmanuel Bonnet medRxiv 2023.05.05.23289561; doi: https://doi.org/10.1101/2023.05.05.23289561

Short-term health system responses to epidemics across hard-to-reach areas in sub-Saharan Africa: A scoping review protocol
Annette Atieno Atieno, Ben Ngoye, Francis Wafula, Gilbert Kokwaro medRxiv 2023.05.05.23289564; doi: https://doi.org/10.1101/2023.05.05.23289564

Characterising Long Covid: a living systematic review update with controlled studies
Melina Michelen, Louise Sigfrid, Christiana Kartsonaki, Ian Shemilt, Claire Hastie, Margaret E. O'Hara, Jake C. Suett, Elisabeth A. Stelson, Polina Bugaeva, Dania T. Dahmsah, Ishmeal Rigby, Daniel Munblit, Eli Harriss, Amanda Burls, Vincent Cheng, Janet T. Scott, Gail Carson, Piero Olliaro, Charitini Stavropoulou medRxiv 2022.08.29.22279338; doi: https://doi.org/10.1101/2022.08.29.22279338

Researching COVID to enhance recovery (RECOVER) pediatric study protocol: Rationale, objectives and design
Unsupervised representation learning improves genomic discovery for lung function and respiratory disease prediction
medRxiv 2023.04.27.23289228; doi: https://doi.org/10.1101/2023.04.27.23289228

Ensuring ethical animal welfare research: Are more ethics review committees the solution?
Birte L Nielsen
Huw D. R. Golledge
Jen-Yun Chou
Irene Camerlink
Péter Pongrácz
Maria Camila Ceballos
Alexandra Whittaker
I. Anna S. Olsson
Last edited: May 6, 2023 UTC
Life Sciences Animal Sciences
Abstract
In this Opinion Paper, we aim to highlight the inherent challenges to ethics review of animal (welfare) science research, especially the differences between different countries and jurisdictions which can give rise to inequalities as articles are reviewed internationally. The article is meant as a debate starter, and we hope that some of the issues raised will inspire animal researchers, journals, and reviewers to improve the process, even though we do not have all the answers.

UKRN Open Research Training Resources and Priorities Working Paper
UK Reproducibility Network
James A. Grange
Last edited: May 6, 2023 UTC
Engineering Law Arts and Humanities Social and Behavioral Sciences Medicine and Health Sciences Architecture Education Physical Sciences and Mathematics Life Sciences Business
UKRN Open Research Programme has released its first working paper about training priorities and resources aimed at accelerating the uptake of high quality open research practices.
Dramatic changes to the transparency, rigor, reproducibility and replicability of research practices have occurred in the last decade. Despite considerable progress towards the adoption of open science practices by researchers in many disciplines, developing pedagogy to train students in open and re...

Wellcome Open Research
https://wellcomeopenresearch.org/browse/articles
[Accessed 06 May 2023]

Shielding individuals at high risk of COVID-19: A micro-simulation study [version 1; peer review: awaiting peer review]
Kevin Van Zandvoort, Caroline Favas, Francesco Checchi

Abstract
Background: One proposed intervention for mitigating COVID-19 epidemics, particularly in low-income and crisis-affected settings, is to physically isolate individuals at high risk of severe disease and death. This intervention, known as ‘shielding’, could be implemented in various ways. If shielding is imperfect, any introduction of infections within the shielding group could cause substantial mortality and negate the intervention’s benefits. We explored the effectiveness of shielding under various modalities of implementation and considered mitigation measures to reduce possible harms.

Methods: We used an individual-based model to simulate a COVID-19 epidemic in a population where a fraction above a given age are relocated to shielding residences. We set our simulation with the context of an internally displaced persons’ camp in Somaliland, for which we had previously collected data on demographics and social mixing patterns. We compared an unmitigated epidemic with a shielding intervention accompanied by various risk-mitigating measures. We explored the impact of parameters such as residence size, reduction in contacts, basic reproduction number, and prior immunity in the population.

Results: Shielded residences are likely to be breached with infection during the outbreak. Nonetheless, shielding can be effective in preventing COVID-19 infections in the shielded population. The effectiveness of shielding is mostly affected by the size of the shielded residence, and by the degree by
which contacts with the outside world are reduced. Reductions in contacts between shielded individuals are only effective in larger shielded residences. In epidemics with a lower reproduction number, the effectiveness of shielding could be negative.

Conclusions: Shielding could be an effective method to protect the most at-risk individuals. It should be considered where other measures cannot easily be implemented, but with attention to the epidemiological situation. Shielding should only be implemented through small to medium-sized shielding residences, with appropriate mitigation measures to prevent subsequent spread.

Systematic Review  Open Access

A rapid review of community engagement and informed consent processes for adaptive platform trials and alternative design trials for public health emergencies [version 1; peer review: awaiting peer review]

Alun Davies, Ilja Ormel, Alexe Bernier, Eli Harriss, Noni Mumba, Nina Gobat, Lisa Schwartz, Phaik Yeong Cheah

Abstract

Background: Public Health Emergencies (PHE) demand expeditious research responses to evaluate new or repurposed therapies and prevention strategies. Alternative Design Trials (ADTs) and Adaptive Platform Trials (APTs) have enabled efficient large-scale testing of biomedical interventions during recent PHEs. Design features of these trials may have implications for engagement and/or informed consent processes. We aimed to rapidly review evidence on engagement and informed consent for ADTs and APTs during PHE to consider what (if any) recommendations can inform practice.

Method: In 2022, we searched 8 prominent databases for relevant peer reviewed publications and guidelines for ADTs/APTs in PHE contexts. Articles were selected based on pre-identified inclusion and exclusion criteria. We reviewed protocols and informed consent documents for a sample of large platform trials and consulted with key informants from ADTs/APT trial teams. Data were extracted and summarised using narrative synthesis.

Results: Of the 49 articles included, 10 were guidance documents, 14 discussed engagement, 10 discussed informed consent, and 15 discussed both. Included articles addressed ADTs delivered during the West African Ebola epidemic and APTs delivered during COVID-19. PHE clinical research guidance documents highlight the value of ADTs/APTs and the importance of community engagement, but do not provide practice-specific guidance for engagement or informed consent. Engagement and consent practice for ADTs conducted during the West African Ebola epidemic have been well-documented. For COVID-19, engagement and consent practice was described for APTs primarily delivered in high income countries with well-developed health service structures. A key consideration is strong communication of the complexity of trial design in clear, accessible ways.

Conclusion: We highlight key considerations for best practice in community engagement and informed consent relevant to ADTs and APTs for PHEs which may helpfully be included in future guidance.

Protocol: The review protocol is published online at Prospero on 15/06/2022: registration number CRD42022334170.

* * * *

Think Tanks

Brookings  [to06 May 2023]
http://www.brookings.edu/
Latest Research [Selected]
No new digest content identified.

**Center for Global Development**  [to 06 May 2023]
https://www.cgdev.org/
All Research [Selected]
No new digest content identified.

**Chatham House**  [to 06 May 2023]
https://www.chathamhouse.org/
Selected Analysis, Comment, Events
No new digest content identified.

**CSIS**  [to 06 May 2023]
https://www.csis.org/
Selected Reports, Events
No new digest content identified.

**Kaiser Family Foundation**  [to 06 May 2023]
https://www.kff.org/search/?post_type=press-release
Newsroom
No new digest content identified.

**McKinsey Global Institute**
https://www.mckinsey.com/mgi/overview
Latest Research
No new digest content identified.

**ODI [Overseas Development Institute]**  [to 06 May 2023]
Publications [Selected]
No new digest content identified.

**Pew Research Center**  [to 06 May 2023]
https://www.pewresearch.org/
Latest Publications [Selected]
No new digest content identified.

**Rand**  [to 06 May 2023]
https://www.rand.org/pubs.html
Published Research [Selected]
Journal Article

**Parental Perceptions Related to Co-Administration of Adolescent COVID-19 and Routine Vaccines**

Our objective was to assess parental preferences to have their adolescents aged 12-17 years receive COVID-19 and other routine vaccines at the same time.

May 2, 2023
Courtney A. Gidengil, Andrew M. Parker, Amber M. Gedlinske, Natoshia M. Askelson, Christine A. Petersen, Megan Lindley, Kate R. Woodworth, Aaron M. Scherer

*Urban Institute*  [to 06 May 2023]
https://www.urban.org/publications

*New Research Publications - Selected*

*Brief*

**The Health Coverage of Noncitizens in the United States 2024**
May 4, 2023

*Research Agenda*

**Transforming Prisons through Research: An Agenda for Sweeping Reform**
May 4, 2023

*World Economic Forum*  [to 06 May 2023]
https://agenda.weforum.org/news/

*Media*

**Breaking Down Barriers: Business, Academia and Government Collaborate on Generative AI Development**
News 01 May 2023

* * * * *

* * * *

---

**Vaccines and Global Health: The Week in Review** is a service of the Center for Vaccine Ethics and Policy (CVEP) / GE2P2 Global Foundation, which is solely responsible for its content.

Copyright GE2P2 Global Foundation 2023. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/) or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there
should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, PATH, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

* * * * * *